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ABSTRACT 
The reinforcing properties of alcohol (ethanol) are associated with activation 
of the mesolimbic dopamine system and the concomitant increase in 
dopamine in the nucleus accumbens (nAc). Changes in this system are 
thought to be a predominant underlying factor in promoting excessive alcohol 
intake and alcohol use disorder. We have previously shown that a 
simultaneous increase in endogenous taurine is required in order for ethanol 
to increase nAc dopamine levels, and hypothesize that taurine, which acts as 
an osmoregulator, is released in order to re-equilibrate the osmotic pressure. 
The intake of taurine has escalated over the last decade due to consumption 
of taurine-containing energy drinks, but whether a long-term intake of taurine 
induces adaptations influencing ethanol-induced dopamine elevation is not 
clear. Thus, the overall aim of this thesis was to investigate correlations 
between taurine and dopamine during ethanol exposure, with special focus on 
the nAc. To this end, behavioral tests were combined with neurochemical 
measurements and gene expression analysis performed in rodents. Our data 
show that systemically administrated taurine enters the CNS, a process that is 
not influenced by sub-chronic taurine treatment. Even though acute exposure 
does not increase locomotion, repeated exposure leads to behavioral 
sensitization to the drug, and taurine combined with caffeine potentiates 
ethanol-induced locomotion, a phenomenon previously linked to the 
reinforcing properties of the drug. By means of in vivo microdialysis we 
show that rats consuming high levels of ethanol respond with a blunted 
taurine elevation in response to acute ethanol treatment, and exhibit a lower 
dopamine tone compared to rats consuming low amounts of ethanol. At the 
same time, repeated taurine exposure does not influence the dopamine 
elevating properties of ethanol. By combining microdialysis with 
pharmacological and chemogenetic manipulations, we found that ethanol-
 induced taurine release is not action potential dependent and may involve 
astrocytes and volume regulated anion channels (VRACs). In conclusion, we 
suggest that increased nAc taurine levels following ethanol exposure mainly 
derives from astrocytes and involves VRACs, supporting an osmoregulatory 
role of taurine. Even though ethanol-induced dopamine release is not 
influenced by sub-chronic taurine exposure, taurine could contribute to the 
increase in alcohol consumption seen in humans drinking alcohol mixed with 
energy drinks. 
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SAMMANFATTNING PÅ SVENSKA 
Taurin- och dopaminrelaterade effekter av etanol – en experimentell studie 
på gnagare  
Alkohol har konsumerats i årtusenden världen över. Idag utgör konsekvenser 
av alkoholkonsumtion ungefär 5% av den globala sjukdomsbördan och 3 
miljoner människor dör varje år på grund av alkoholrelaterade skador. De 
skador som alkoholen medför är inte enbart begränsade till den enskilda 
individen utan även familj, vänner och samhället påverkas negativt. När 
konsumtionen blir skadlig och ett antal diagnoskriterier uppfylls används 
sjukdomstermen Alcohol Use Disorder (AUD). Sjukdomen är ett kroniskt 
tillstånd som orsakar psykisk så väl som fysisk ohälsa och 
samhällskostnaderna för alkoholrelaterade sjukdomar är enorma både i 
Sverige och globalt. De farmakologiska behandlingar som finns tillgängliga 
för AUD-patienter idag har begränsade effekter och många återfaller i 
alkoholmissbruk. För att på sikt kunna ta fram en förbättrad 
läkemedelsbehandling behöver vi ökade kunskaper om de mekanismer som 
ligger till grund för utvecklingen av AUD. Alkohol (etanol) och andra 
beroendeframkallande droger aktiverar det mesolimbiska dopaminsystemet, 
som är en del av hjärnans belöningssystem. Denna aktivering resulterar i 
ökade dopaminnivåer i nucleus accumbens (nAc), vilket ger en känsla av 
välbehag. Vår forskning har tidigare visat att för att etanol ska kunna aktivera 
det mesolimbiska dopaminsystemet så krävs en frisättning av den kroppsegna 
aminosyran taurin. Det övergripande syftet med denna avhandling var att 
kartlägga interaktionen mellan taurin och dopamin vid etanol-inducerat 
beteende och neurotransmission hos obehandlade så väl som etanol- eller 
taurin-förbehandlade djur.  
Då förändringar i det mesolimbiska dopaminsystemet har föreslagits ligga till 
grund för en överdriven alkoholkonsumtion ville vi i den första studien 
(paper I) undersöka om den etanolinducerade taurin/dopaminfrisättningen i 
nAc var förändrad efter sju veckors frivilligt alkoholintag. Genom att 
genomföra in vivo mikrodialys studier på Wistar råttor fann vi att de råttor 
som valde att konsumera stora mängder etanol hade en lägre och 
långsammare ökning av taurin när de exponerades för etanol. Dessa djur hade 
också lägre dopaminnivåer i nAc jämfört med djur som valt att dricka små 
mängder etanol. Om dessa förändringar är en konsekvens av alkoholintaget, 
eller om genetiska skillnader från början påverkat konsumtionen, är i nuläget 
inte känt. Framtida studier får utvisa om det finns ett kausalt samband mellan 
ett dämpat etanolinducerat taurinsvar och en låg dopaminerg ton.  
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Då intaget av taurin har ökat kraftigt det senaste årtiondet, mycket på grund 
av konsumtion av taurininnehållande energidrycker, ville vi i den andra 
studien (paper II) undersöka om den etanolinducerade taurin-
/dopaminfrisättningen i nAc var förändrad efter långvarig exponering för 
höga doser av taurin. Vi fann att en längre tids behandling med taurin inte 
påverkar dess förmåga att passera från blodet till hjärnan eller taurinnivåerna 
i nAc. Även om upprepad behandling med taurin leder till en ökad känslighet 
för ämnets lokomotorstimulerande egenskaper, ett beteende som tidigare 
kopplats samman med en ökad dopaminaktivitet i det mesolimbiska 
dopaminsystemet, så påverkar upprepad exponering av taurin inte 
dopaminfrisättningen efter en akut injektion med etanol. En av 
taurinmolekylens viktigaste egenskaper i kroppen är att fungera som en 
osmoreglerare. Vi tror därför att alkohol ger en frisättning av taurin för att 
balansera vätsketrycket över cellmembranet och på så sätt motverka 
cellsvullnad. I den tredje studien (paper III) ville vi definiera från vilken typ 
av celler som taurin frisätts efter etanolexponering och hur denna frisättning 
sker. I ett flertal mikrodialysstudier blev råttorna lokalt behandlade med 
nervcells- eller astrocythämmande substanser och därefter etanol. 
Sammantaget drog vi slutsatsen att den etanolinducerade taurinökningen 
kommer från astrocyter, inte nervceller, och att frisättningen framförallt 
medieras via volymreglerande kanaler (VRACs). 
I energidrycker förekommer förutom koffein ofta stora mängder taurin, och 
intag av energidrycker i kombination med alkohol har visats öka risken för en 
skadlig alkoholkonsumtion och även AUD. Individer som konsumerar 
kombinationen uppvisar ett försämrat omdöme, vilket medför att de utsätter 
både sig själva och andra för risker. För att studera om detta beror på en 
farmakologisk interaktion gavs möss en akut injektion med olika 
koncentrationer och kombinationer av etanol, taurin och koffein, och djurens 
lokomotoraktivitet registrerades. Administrering av etanol eller koffein gav 
upphov till en signifikant ökning av lokomotionen, men inte taurin. Även om 
taurin inte påverkade etanol-inducerad lokomotion i sig själv, sågs en 
potentiering vid administrering tillsammans med koffein och etanol vid 
specifika doskombinationer (paper IV). Ökad lokomotion är ett fenomen som 
tidigare har associerats till drogers positivt förstärkande egenskaper. Detta 
skulle därför kunna innebära att taurin, troligen tillsammans med koffein, 
bidrar till den ökade alkoholkonsumtion som rapporterats hos människor som 
förtär alkohol i kombination med energidrycker. 
Sammanfattningsvis tyder fynden i denna avhandling på att de ökade 
taurinnivåerna i nAc efter exponering för etanol är ett robust fenomen, och att 
denna taurinfrisättning huvudsakligen härrör från astrocyter och inbegriper 
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volymreglerande kanaler. Resultaten tyder också på att de kroppsegna 
nivåerna av taurin i hjärnan är hårt reglerade och inte påverkas av upprepad 
exponering för etanol eller taurin. Vidare föreslår vi att systemisk 
administrering av taurin kan ha långvariga effekter i hjärnan, som i den 
aktuella avhandlingen visas som beteendemässig sensitisering, men att 
upprepad exponering för taurin inte påverkar hur eller i vilken grad etanol 
ökar dopamin. Slutligen, det är möjligt att en interaktion mellan taurin, 
koffein och etanol kan orsaka ett ökat alkoholintag hos personer som blandar 
energidrycker med alkohol.  
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INTRODUCTION 
Alcohol use disorder (AUD)  
Alcohol, a psychoactive substance with an addictive potential, has been used 
worldwide in many different cultures for thousands of years. Today, 5.1% of 
the global burden of disease and injury is attributed to alcohol intake.  
Excessive alcohol use is a leading risk factor for premature death, and 
worldwide 3 million people die from alcohol-related causes every year. The 
harmful use of alcohol is not only restricted to the particular individual, it 
also causes harm to family, friends as well as society. In addition to causing a 
significant health and social loss, alcohol has a great impact on the economic 
burden of the society (WHO, 2019). The annual cost in Sweden is estimated 
to 66 billion SEK (Svenska Folkhälsomyndigheten, 2019). When the 
consumption becomes severe, a physician can explore where Alcohol use 
disorder (AUD) is present. There are no quantitative or physiological 
assessments to use in order to confirm AUD. Instead, the diagnosis is based 
on fulfilling a certain number of criteria congregated in diagnostic manuals, 
The Diagnostic and Statistical Manual of Mental Disorders of the American 
Psychiatry Association, 5th edition (DSM-5) (table 1) or ICD-11 by WHO, 
used by physicians. Long-term alcohol consumption is a casual factor for 
more than 200 medical conditions (WHO, 2019), including various types of 
malign neoplasms, such as cancer in both the upper and lower digestive tract 
and breast cancer, but also cardiovascular and circulatory diseases 
(hypertension, dysrhythmias, stroke) as well as digestive diseases (hepatic 
steatosis, alcoholic hepatitis, cirrhosis) (Shield et al., 2013). During 
prolonged drinking also brain atrophy and neurodegeneration occur leading 
to impairment of neurological function e.g. deficits in visuo-spatial and 
verbal learning, problem solving, memory function and perceptual motor 
skills and motor function (Harper & Matsumoto, 2005). 
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Table 1. The presence of at least two of these criteria during the last 12 
months indicates an Alcohol Use Disorder (AUD). The number of criteria 
fulfilled defines the severity of the AUD. Mild: 2 to 3 criteria, moderate: 4 to 
5 criteria, and severe: 6 or more criteria (American Psychiatry Association, 
2013). 
 
DSM-5 criteria for Alcohol Use Disorder 
 
1. Had times when you ended up drinking 
more, or longer then you intended. 
7. Given up or cut back on activities that were 
important or interesting to you, or gave you 
pleasure, in order to drink. 
2. More than once wanted to cut down or stop 
drinking, or tried to, but couldn’t. 
8. More than once gotten into situations while 
or after drinking that increased your chances 
of getting hurt (such as driving, swimming, 
using machinery, walking in a dangerous 
area, or having unsafe sex). 
3. Spent a lot of time drinking. Or being sick 
or getting over other aftereffects. 
9. Continued to drink even though it was 
making you feel depressed or anxious or 
adding to another health problem. Or after 
having had a memory blackout. 
4. Wanted a drink so badly you couldn’t 
think of anything else. 
10. Had to drink much more than you once 
did to get the effect you want. Or found that 
your usual numbers of drinks had much less 
effect than before. 
5. Found that drinking - or being sick from 
drinking - often interfered with taking care of 
your home or family. Or caused job troubles. 
Or school problems. 
11. Found that when the effects of alcohol 
were wearing off, you hade withdrawal 
symptoms, such as trouble sleeping, 
shakiness, restlessness, nausea, sweating, a 
racing heart, or a seizure. Or sensed things 
that were not there. 
6. Continued to drink even though it was 
causing trouble with your family or friends. 
 
 
 
Pharmacotherapy 
For treating AUD both pharmacotherapy and psychosocial interventions are 
used. The treatment goal is achievement of abstinence, reduction in 
frequency and severity of relapse, and improvement in health and 
psychosocial functioning (European Medical Agency, 2010). To date, there 
are three drugs approved for the treatment of AUD by both the European 
Medical Agency (EMA) and the US Food and Drug Administration (FDA); 
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disulfiram, acamprosate and naltrexone. EMA have approved a fourth drug, 
nalmefene. Disulfiram inhibits the enzyme aldehyde dehydrogenase from 
degrading alcohol’s primary metabolite acetaldehyde. The accumulation of 
acetaldehyde results in unpleasant feelings, such as headache, facial flushing, 
vomiting and chest pain among others (Barth & Malcolm, 2010). Disulfiram 
is the oldest of these drugs and acts as an aversive therapy, while the other 
three drugs belong to the new generation of pharmacological treatments. 
Acamprosate is a homotaurine analogue which mechanism of action has been 
suggested to involve inhibitory (GABAergic; (Boismare et al., 1984; Daoust 
et al., 1992) or glycinergic; (Chau et al., 2010b; Chau et al., 2018)) or 
excitatory neurotransmission, including modulation of N-methyl-D-aspartic 
acid (NMDA) or metabotropic glutamate receptors (mGluR), with restored 
balance between excitatory and inhibitory neurotransmission as a result 
(Rammes et al., 2001; Harris et al., 2002; Harris et al., 2003). However, 
Spanagel and colleagues have suggested that it is the calcium moiety of the 
acamprosate molecule that is responsible for the pharmacological effect 
(Spanagel et al., 2014). Naltrexone prevents the reinforcing effect of alcohol 
by acting as a competitive opioid receptor antagonist (O'Brien et al., 1996). 
Nalmefene is also an opioid receptor antagonist with similar effects as 
naltrexone. However, unlike naltrexone, it has a partial agonistic effect at 
kappa opioid receptors, whereas naltrexone acts as a full antagonist at these 
receptors (Swift, 2013). Although these pharmacological treatments are 
available for patients with AUD, the effect sizes are poor (Kranzler & Van 
Kirk, 2001), and there is a great need for improved pharmacotherapy. To this 
end, studying mechanisms involved in the action of alcohol in the brain 
reward system is of high importance.  
Addiction 
Addiction is a chronic and relapsing brain disorder (McLellan et al., 2000), 
characterized by loss of control over drug intake, impulsive drug seeking and 
intake despite adverse effects (DSM-5, table1). Discontinuation of drug 
intake may lead to physical as well as psychological withdrawal symptoms 
(Weiss & Koob, 2001), fulfilling one of the diagnostic criteria for AUD 
according to DSM-5 (table 1). Addiction is a heterogenic disorder and the 
lead period from recreational drug use to addiction is highly individual. The 
mechanisms underlying addiction probably involve several different 
neurocircuits and structures (Koob & Volkow, 2010), and social, 
environmental and developmental factors, as well as sex, personality traits 
and genetics, all have been shown to contribute to addiction development 
(Cloninger et al., 1981; Cloninger, 1987; Chartier et al., 2010; Bobzean et 
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al., 2014). The development of addiction also depends on the drug and 
exposure, as drugs differ in their addictive profile with alcohol representing 
one of the six most addictive drugs (Nutt et al., 2007).  
The neurobiological mechanisms behind the shift from impulsive to 
compulsive drug intake and the development of “loss of control” involve 
disruption of brain circuits involved in reward, learning and control (Koob & 
Volkow, 2010). In the early stages of drug intake the nucleus accumbens 
(nAc) plays an important role and mediates the rewarding sensation of the 
drug. However, it has been proposed that during the progression from 
impulsive and reward-driven behavior to compulsive and habit-driven drug-
seeking behavior there appears to be neuroanatomical progression from the 
nAc to the dorsal striatum (DS), a key brain region for habit formation 
(Gerdeman et al., 2003; Koob & Volkow, 2010). The development of 
addiction has in several review articles (Koob & Le Moal, 1997; Koob & 
Volkow, 2010; 2016) been described as a cycle composed of three stages: 
binge/intoxication, withdrawal/negative affect and 
preoccupation/anticipation. With repeated drug exposure the cycle is 
intensified and is believed to eventually result in the pathological state of 
addiction. During the binge/intoxication stage the drug is consumed due to its 
positive reinforcing effects and engages dopamine transmission in the nAc 
and then engages stimulus-response habits in the DS. Overstimulation of the 
reward system leads to loss of control and bingeing. At the 
withdrawal/negative affect stage the drug intake is rather driven by removal 
of aversive symptoms associated with withdrawal such as irritability, stress 
and anxiety, which have been tied to changes in the extended amygdala. The 
third stage, preoccupation/anticipation, involves processing of conditioned 
reinforcement by basolateral amygdala and contextual cues by the 
hippocampus and their interaction with the prefrontal cortex, which helps to 
execute desires despite negative consequences. Thus, this third stage of the 
addiction cycle is hypothesized to be a key component of relapse, a 
characteristic feature of the disorder  
The brain reward system 
The brain reward system regulates reward and motivation. The pleasurable 
feeling of natural rewards is essential for survival of the species; motivating 
the individual to engage in eating, mating and social interactions, and are 
therefore highly conserved among species. In the 1950s Olds and Milner 
initiated the discovery of what today is referred to as the brain reward system. 
They demonstrated that rats implanted with an electrode in the brain would 
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press a lever to receive electrical stimulation in certain brain areas. These 
areas were termed “reinforcing structures” (Olds & Milner, 1954). These 
pioneering researchers suggested that the stimulated brain areas were of 
importance for the pursuit of natural rewards such as food and sex. It was 
later shown that numerous drugs of abuse exert their habit-forming effect in 
these areas. Consequently, a common neuroanatomical circuitry of electrical 
self-stimulation, natural rewards and drugs of abuse was proposed (Wise, 
1996). These “reinforcing structures” were later mapped and defined as the 
brain reward system. The reward system consists, among other areas, of the 
medial forebrain bundle, hippocampus, ventral tegmental area, amygdala, 
frontal cortex, septal and striatal regions (German & Bowden, 1974; Milner, 
1991). Both drugs of abuse and natural rewards activate the reward system. 
However, drugs of abuse activate the system in a way that leads to stronger 
effects. Effects, that may in turn lead to neuronal changes and eventually 
addiction (Wise & Rompre, 1989).  
Dopamine and the mesolimbic dopamine system 
Dopamine is one of the three catecholamines (noradrenalin and adrenalin are 
the other two) and is synthesized both in neuronal terminals and in cell 
bodies in several different brain regions, but predominantly in the ventral 
tegmental area (VTA) and substantia nigra (Carlsson et al., 1964; Dahlstrom 
& Fuxe, 1964). Dopamine is synthesized from the amino acid tyrosine, which 
is converted from phenylalanine in the dopamine neuron or transported over 
the blood-brain barrier into the brain. In the neuron tyrosine is converted to 
dihydroxyphenylalanine (L-DOPA), which then is decarboxylated to 
dopamine, where the hydroxylation of tyrosine to L-DOPA is the rate-
limiting step of the synthesis. Dopamine is packed into vesicles located in the 
nerve terminal, released by exocytosis upon arrival of an action potential and 
binds to dopamine receptors. The synaptic cleft is cleared from dopamine by 
reuptake via the dopamine transporter and repacked to vesicles or degraded, 
mainly by two enzymes, catechol-O-methyltransferase (COMT) and 
monoamine oxidase (MAO), resulting in the end-metabolite homovanillic 
acid (HVA) (Elsworth & Roth, 1997).  
An important pathway of the brain reward system is the mesolimbic 
dopamine system (Engel & Carlsson, 1977; Wise & Bozarth, 1987), which is 
one of four dopamine pathways in the brain. In 1958, Arvid Carlsson and 
colleagues discovered dopamine as a neurotransmitter (Carlsson et al., 1958). 
Subsequently, it was shown that dopaminergic cell bodies were 
predominantly located within the VTA and substantia nigra (Carlsson et al., 
1964; Dahlstrom & Fuxe, 1964). Dopaminergic neurons that project from the 
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VTA to the prefrontal cortex constitute the mesocortical dopamine system, 
which is involved in cognitive control, emotional response and motivation 
(Volkow et al., 2004; Cools, 2008; Russo & Nestler, 2013). Dopaminergic 
neurons from the VTA also project to the nAc, amygdala and hippocampus 
and is therefore entitled the mesolimbic dopamine system. Much attention 
has been focused on the projection from the VTA to the nAc as it has been 
shown to be highly involved in mediating reward and reinforcing effects, 
including those of drugs of abuse (Le Moal & Simon, 1991; Kelley & 
Berridge, 2002). The nigrostriatal dopamine system where dopamine neurons 
project from the substantia nigra to the dorsal striatum has been shown to be 
involved in motor activation (Obeso et al., 2008; Trudeau et al., 2014) and 
habit-formation (Gerdeman et al., 2003; Faure et al., 2005). 
Dopamine neurons have the ability to fire in two distinct manners: a phasic 
burst firing and tonic firing (Grace & Bunney, 1984a; b). Positive 
reinforcement is mainly associated with burst firing of the dopamine neurons, 
while tonic firing is responsible for maintaining basal levels of dopamine and 
to engage in cognitive, motivational and motor functions (Marinelli & 
McCutcheon, 2014). Dopaminergic cells in the VTA are under inhibitory 
control of GABAergic (γ-aminobutyric acid) interneurons within the VTA 
and GABAergic afferents from the nAc and ventral pallidum (Conrad & 
Pfaff, 1976). The excitatory afferents to the VTA are mainly glutamatergic 
and originates from the PFC, laterodorsal tegmental nucleus (LDTg), bed 
nucleus of the stria terminalis and lateral hypothalamus (Omelchenko & 
Sesack, 2007). Furthermore, cholinergic neurons projecting from the LDTg 
and pedunculopontine tegmental nucleus (PPTg) to the VTA enable 
dopaminergic phasic firing, via activation of nicotinic acetylcholine receptors 
(nAChR) (Blaha et al., 1996).  
The predominant class of neurons within the nAc is GABAergic medium 
spiny neurons (MSNs). There are five different types of dopamine receptors, 
which are classified as D1-like (D1 and D5) and D2-like (D2, D3 and D4) 
based on structure, biochemistry and pharmacology (Beaulieu & 
Gainetdinov, 2011). Both dopamine receptor 1 (D1R) and dopamine receptor 
2 (D2R) are located on nAc MSNs (Gerfen, 1992). nAc D1R MSNs directly 
inhibit the dopaminergic ventral mesencephalon (the direct pathway), leading 
to disinhibition of the thalamus and promote motivated behavior. The nAc 
D2R MSNs inhibits the ventral pallidum, which inhibits the ventral 
mesencephalon (the indirect pathway), resulting in inhibition of the thalamus 
and motivated behavior (Kupchik & Kalivas, 2017). Furthermore, it has been 
demonstrated that activation of nAc D2R MSNs suppresses cocaine reward, 
whereas the opposite was shown for D1R MSNs (Lobo et al., 2010). The 
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opposite effects of these two subtypes of nAc MSNs is consistent with the 
role of D1R and D2R MSNs in the dorsal striatum, where the direct (D1R 
containing) and indirect (D2R containing) pathways produce balanced 
behavioral output by acting in opposition (Albin et al., 1989; Graybiel, 
2000). However, emerging results suggests that the direct and indirect 
pathways of the nAc are not coded by MSN cell types. Kupchik and co-
workers demonstrated that D1R-MSNs includes a portion of the classical 
indirect pathway by synapsing on ventral pallidum neurons that project to the 
ventral mesencephalon. Conversely, they demonstrated that nAc D2R-MSNs 
target ventral pallidum neurons that innervate the thalamus directly. Thus, 
these D2R-MSNs constitutes a direct pathway through the ventral pallidum 
that disinhibits the thalamus (Kupchik et al., 2015). The nAc can be 
anatomically subdivided in two distinct regions; the core and shell (Zahm & 
Brog, 1992). The two subregions differ in their innervations and are 
functionally distinct. Dopaminergic innervation of the core is associated with 
the nigrostriatal system and dopaminergic innervation of the shell with the 
mesolimbic dopamine system (Deutch & Cameron, 1992). Besides 
dopaminergic innervation, the nAc also receives glutamatergic input, where 
the core receives glutamatergic control mainly from the prelimbic cortex and 
basolateral amygdala. The shell receives input from a larger number of areas 
such as the infralimbic cortex, ventral hippocampus, thalamus and the VTA 
(Gipson et al., 2014). It has been suggested that dopamine has opposing roles 
within the core and shell regarding limbic information processing, as 
dopamine in the core is important for amygdala-dependent appetitive 
learning, whilst dopamine in the shell is important for hippocampal-
dependent spatial control (Ito & Hayen, 2011). Furthermore, the shell appears 
to be of importance for reward induced by drugs of abuse. The core on the 
other hand is of importance for goal-directed behaviors (Ito et al., 2004). 
Dopamine and drugs of abuse 
The increase of accumbal dopamine mediating the pleasurable feeling of 
natural rewards is the primary function of the brain reward system. However, 
most drugs of abuse, including alcohol, also increase dopamine in the nAc 
and give rise to an even greater dopamine response than natural rewards. 
Since both the amount and rate of dopamine increase is associated with the 
subjective sensation of the so-called “high”, where a fast dopamine release 
and high amounts is positively correlated with the feeling of high (Volkow et 
al., 1999; 2003; Koob & Volkow, 2016), drugs of abuse give rise to a greater 
feeling of “high” than natural rewards. Dopamine is also essential for 
motivation, memory and executive function (Volkow et al., 2012), important 
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components in associative reward-related learning, which in turn is facilitated 
by dopamine increase in the nAc (Di Chiara, 1999).  
The role of dopamine in addiction and reward is complicated. As mentioned 
above, not all drugs of abuse increase dopamine. Barbiturates, 
benzodiazepines and inhalants do not increase dopamine although they are 
rewarding and often abused (Wise, 1987; Koob, 1992; Balster, 1998). 
Administration of dopamine antagonists or lesioning of dopamine neurons 
decreases self-administration of several drugs (Roberts et al., 1980; Corrigall 
et al., 1992; Di Chiara et al., 2004) but not of opiates and ethanol (Pettit et 
al., 1984; Dworkin et al., 1988; Rassnick et al., 1993). On the other hand, 
low doses of dopamine antagonists have been shown to increase drug self-
administration, (Yokel & Wise, 1975; Corrigall & Coen, 1991), which is 
commonly explained as a compensatory intake due to a blunted drug 
response. Dopaminergic neurons may also fire in response to aversive 
stimuli. However this response appears to be heterogeneous and segregated 
based on the location of dopamine neurons in the brain. For example in the 
rat, excitation induced by aversive stimuli is more likely to occur of neurons 
located in the lateral and ventral VTA than neurons located in the medial and 
dorsal VTA (Brischoux et al., 2009; Valenti et al., 2011; Marinelli & 
McCutcheon, 2014). Although, most researchers believe that the primary 
function of the mesolimbic dopamine pathway is to mediate reward, the 
variety of effects mediated by dopamine needs to be further elucidated in 
detail.  
The pharmacology of ethanol 
There are alcohols with different number of carbon atoms, where the alcohol 
used for human consumption contains two carbons and is entitled ethanol. 
Ethanol is the alcohol used in the studies that comprises this thesis, and the 
two will be used as synonyms. Due to the hydrophilic and lipophilic 
properties of the molecule ethanol has the ability to easily cross biological 
membranes such as the blood-brain barrier by passive diffusion into the 
central nervous system (CNS). Alcohol is metabolized in the liver by the 
enzymes alcohol dehydrogenase and cytochrome P450 to acetaldehyde, 
which is then converted to acetic acid by aldehyde dehydrogenase and finally 
broken down to carbon dioxide and water (Pohorecky & Brick, 1988). 
Ethanol produces a number of different effects in humans that are both 
stimulative and sedative. At low doses ethanol produces disinhibition, 
euphoria and anxiolysis. At higher doses ethanol acts as a depressant 
resulting in impaired motor function and cognition and will eventually, with 
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increasing dose, lead to vomiting, unconsciousness and possible death 
(Hendler et al., 2013).  
Ethanol and ligand-gated ion channels 
Ethanol has a rich and complex pharmacology and interacts with several 
different receptor systems, especially ligand-gated ion channels, where the 
interaction can take place both in a direct and indirect manner. Factors such 
as time of exposure and concentration of ethanol, as well as the receptor 
subunit composition appear to exert a high impact (Vengeliene et al., 2008). 
In general, ethanol enhances the function of GABAA receptors (γ-
aminobutyric acid receptor subtype A), glycine receptors (GlyR), 5-
hydroxytryptamine (serotonin) subtype 3 receptors (5-HT3R) and nAChR 
(Lovinger, 1999; Mihic, 1999; Narahashi et al., 1999), and inhibits NMDA 
receptor (NMDAR) and purinergic P2X subtype 4 receptor (P2X4R) function 
(Lovinger et al., 1989; Franklin et al., 2014), Besides interacting with ligand-
gated ion channels ethanol is also known to inhibit L-type Ca2+ channels 
(Wang et al., 1994), and open G-protein activated inwardly rectifying K+ 
channels (Kobayashi et al., 1999; Lewohl et al., 1999). Below follows a very 
brief description of ethanol’s interaction with these receptor systems.  
Ethanol potentiates GABAA receptor activity both direct and indirectly 
(Vengeliene et al., 2008). Administration of GABA antagonists to rodents 
blocks the sedative effects of ethanol (Cott et al., 1976; Liljequist & Engel, 
1982), and facilitation of GABAergic neurotransmission appears to be 
involved in ethanol’s anxiolytic effect and ethanol-induced impaired 
cognitive function as well as motor function (Ticku, 1990; Davies, 2003). 
The impact of ethanol on GABAergic transmission appears to be complex, 
depending on the concentration of ethanol, receptor localization as well as 
receptor subtype (Aguayo et al., 2002; Korpi et al., 2007; Kumar et al., 
2009). The time of ethanol exposure is also of importance as short-term 
consumption increases receptor function, whilst long-term consumption 
decreases it (Morrow et al., 1990; Mihic, 1999; Davies, 2003). It has been 
shown that several of the candidate genes for AUD codes for GABAARs and 
GlyRs (Korpi et al., 2007). Ethanol enhances GlyR function (Perkins et al., 
2010), which may be a consequence of a direct interaction of ethanol with a 
group of amino acids that form a hydrophobic binding site for ethanol on the 
receptor (Harris et al., 2008; Howard et al., 2014; Burgos et al., 2015). The 
binding site appears to be located at the transmembrane domain 2 and 3 
(TM2, TM3), as mutations in these domains of the alpha subunit of the 
glycine receptor reduced or eliminated the ability of ethanol to potentiate 
glycine currents (Borghese et al., 2012). Also residues of the loop 2 in the 
Taurine and dopamine-related effects of ethanol 
10 
extracellular region of the receptor constitute the binding site (Crawford et 
al., 2007). It has also been proposed that ethanol enhances GlyR function, by 
increasing levels of taurine, a ligand for the GlyR, in the nAc (De Witte et al., 
1994; Adermark et al., 2011b; Ericson et al., 2011; Ericson et al., 2019), 
which in turn has been shown to increase dopamine in the same region and in 
a strychnine dependent manner (Ericson et al., 2006). The role of taurine in 
ethanol-induced dopamine increase will be discussed further in the 
subchapter “Interactions between taurine and ethanol in the CNS”. Further it 
has been shown that glycine reuptake inhibitors decrease ethanol preference- 
and consumption in rats (Molander et al., 2007; Lido et al., 2012). Ethanol 
acts as a co-agonist at the nAChR and enhances the effect of acetylcholine 
(ACh) and nicotine if present (Marszalec et al., 1999). nAChR in the VTA 
are indirectly involved in the ethanol-induced accumbal dopamine elevation 
(Blomqvist et al., 1997; Ericson et al., 2003; Ericson et al., 2008). Ethanol 
potentiates the effects of 5-HT by direct interaction with the 5-HT3R 
(Lovinger, 1991; Lovinger & White, 1991). Pharmacological manipulations 
of the serotonergic system and transgenic mice model indicate an 
involvement of this neurotransmitter in voluntary ethanol consumption 
(Engel et al., 1998; Zhou et al., 1998; Vengeliene et al., 2008; Kasper et al., 
2013), and 5-HT3R antagonism inhibited ethanol-induced dopamine release 
in the nAc (Carboni et al., 1989). The effects of ethanol on the NMDAR 
appear so be exposure-dependent. Acute ethanol exposure results in inhibited 
receptor function, whilst receptor expression and function are increased 
during long-term exposure (Iorio et al., 1992; Dodd et al., 2000). Neuronal 
degeneration and cognitive impairment caused by ethanol are thought to be 
mediated by NMDA receptors (Vengeliene et al., 2008). Furthermore, studies 
using NMDAR antagonists suggest that glutamate neurotransmission in the 
nAc modulates ethanol-self administration and reinforcement (Rassnick et 
al., 1992; Biala & Kotlinska, 1999). It has been suggested that ethanol 
inhibits P2X4R function by acting as a negative allosteric modulator, shifting 
the adenosine triphosphate (ATP) concentration response curve to the right 
(Davies et al., 2002; Davies et al., 2005), and that also this receptor is 
involved in alcohol drinking behavior (Franklin et al., 2014). Expression 
levels of the receptor messenger RNA (mRNA) is negatively correlated with 
alcohol intake (Tabakoff et al., 2009), and mice lacking the P2X4R gene 
consume more ethanol than wild type controls (Wyatt et al., 2014). 
Ivermectin, a positive modulator of P2X4R antagonizes ethanol-mediated 
inhibition of P2X4R (Asatryan et al., 2010), and attenuates ethanol 
consumption and preference in mice (Yardley et al., 2012; Asatryan et al., 
2014). 
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Ethanol and dopamine 
Some of the first studies pointing towards a dopamine elevating property of 
ethanol were locomotor activity studies performed in mice. They showed that 
ethanol increased locomotion, a behavior related to ethanol-induced 
activation of the mesolimbic dopamine system (Carlsson et al., 1974; 
Liljequist et al., 1981; Wise & Bozarth, 1987; Engel et al., 1988). Studies 
using in vivo microdialysis later confirmed the ability of ethanol to increase 
dopamine in the nAc. This is a robust phenomenon occurring regardless of 
whether alcohol is orally- (Weiss et al., 1993) or systemically administrated 
(Di Chiara & Imperato, 1988; Jerlhag et al., 2014; Ericson et al., 2019), or 
perfused locally in the nAc (Yoshimoto et al., 1992; Ericson et al., 2003). 
Even the anticipation of alcohol has been shown to increase dopamine, and 
this increase could be part of the mechanisms underlying cue-induced relapse 
to alcohol intake (Weiss et al., 1993; Lof et al., 2007; Soderpalm et al., 
2009). 
All of the different types of dopamine receptors appear to be involved in the 
actions of ethanol in the brain reward system. For example, the 
administration of agonists or antagonists of D1, D2 and D3 receptors 
influence ethanol intake (Pfeffer & Samson, 1988; Russell et al., 1996; 
Cohen et al., 1998), and antagonism of these three receptors reduce cue-
induced reinstatement of alcohol-seeking behavior (Liu & Weiss, 2002; 
Vengeliene et al., 2006). Furthermore, in particular the D2 receptor appears 
to be highly influenced by chronic alcohol intake both in humans and 
animals. In AUD patients, a reduction in both D2 receptor function and 
availability has been reported (Balldin et al., 1993; Volkow et al., 1996), and 
voluntary long-term alcohol consumption in rats reduced the mRNA 
expression of the D2 receptor within the nAc (Jonsson et al., 2014; Feltmann 
et al., 2018). Inversely, high levels of the D2 receptor may be protective 
against excessive alcohol intake, as overexpression of the receptor in the nAc 
has been shown to decrease ethanol preference as well as consumption in rats 
(Thanos et al., 2001). Endogenous dopamine levels in the nAc are decreased 
in rats after long-term ethanol consumption (Diana et al., 1993; Feltmann et 
al., 2016). Reduced dopaminergic activity in the mesolimbic dopamine 
system has also been reported in AUD patients (Volkow et al., 2007). If 
decreased dopaminergic activity is a cause or consequence of long-term 
alcohol intake is still a matter of debate.  
The nAc-VTA-nAc circuit controlling ethanol-induced dopamine 
During the last two decades, the present research group has formed a 
hypothesis about a neuronal circuitry mediating the dopamine elevating effect 
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of ethanol, involving GlyR in the nAc and nAChR in the VTA, where the 
endogenous amino acid taurine plays a key role. 
Both systemic and local (VTA) administration of the nAChR antagonist 
mecamylamine inhibit accumbal dopamine increase after systemic ethanol 
administration (Blomqvist et al., 1993; Blomqvist et al., 1997). Thus, a direct 
interaction of ethanol with nAChR in the VTA was hypothesized. However, 
when ethanol was perfused in the nAc a dopamine increase in the same 
region was detected, but not when perfused in the VTA (Ericson et al., 2003; 
Lof et al., 2007). This dopamine increase was prevented following 
administration of mecamylamine in the VTA, which also reduced voluntary 
ethanol-intake and preference (Ericson et al., 1998; Ericson et al., 2003; 
Ericson et al., 2008). Furthermore, voluntary ethanol-intake was 
demonstrated to increase both ACh in the VTA and dopamine in the nAc 
(Larsson et al., 2005). These results were interpreted as activation of nAChR 
in the VTA, by increased levels of ACh in the same region, is preceded by an 
action of ethanol in the nAc. Thus, the first hypothesis of a direct interaction 
of ethanol with nAChR was revised to an indirect interaction.  
It was demonstrated that tonically activated strychnine-sensitive GlyRs are 
expressed in the nAc and that they are of importance both for regulating 
dopamine levels per se, as well as ethanol-induced dopamine levels 
(Molander & Soderpalm, 2005b; a). In addition, this receptor population was 
also found to modulate voluntary ethanol intake as demonstrated by local 
(nAc) administration of glycine or the glycine receptor antagonist strychnine 
(Molander et al., 2005). However, as there are few glycine immunoreactive 
fibers or cell bodies in the nAc (Rampon et al., 1996), other endogenous 
ligands could participate in the activation of the GlyR. Indeed, local (nAc) 
administration of the endogenous amino acid taurine was shown to increase 
dopamine levels in the same region. This taurine-induced dopamine increase 
was, like shown for ethanol, inhibited by perfusion of strychnine in the nAc 
and mecamylamine in the VTA (Ericson et al., 2006). Later, it was also 
demonstrated that an endogenous increase in accumbal taurine is required for 
ethanol to increase dopamine in the same region (Ericson et al., 2011).  
Taken together, ethanol is proposed to increase extracellular dopamine levels 
in the following manner: ethanol administration results in increased taurine 
levels, which activates GlyR in the nAc, presumably located on GABAergic 
neurons projecting to the VTA, leading to disinhibition of cholinergic 
neurons from the LDTg/PPTg and increased ACh output in the VTA. 
Subsequently, activation of nAChR in the VTA, presumably located on 
dopaminergic neurons projecting to the nAc, leads to increased accumbal 
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dopamine output (Soderpalm et al., 2009) (fig. 1). By which mechanism 
ethanol increases endogenous taurine levels is not fully understood, and is 
one of the aims to explore in this thesis.  
Figure 1. Schematic illustration of the hypothesized nAc-VTA-nAc circuitry. Taurine may 
interact with GlyR located on GABAergic neurons in the nAc. This results in increased 
acetylcholine levels in the VTA, leading to activation of nAChR on dopaminergic neurons 
projecting from the VTA to the nAc, and finally increased extracellular dopamine levels in 
the nAc. Image adopted with permission from Pei Pei Chau. GlyR=glycine receptor, 
nAChR=nicotinic acetylcholine receptor, nAc=nucleus accumbens, VTA=ventral 
tegmental area, LDT/PPTg= laterodorsal/pedunculopontine tegmental nucleus 
Taurine 
Taurine (β-amino ethane sulphonic acid), often referred to as an amino acid, 
is in the strict sense not an amino acid as it contains a sulfo group instead of 
the characteristic carboxyl group. The molecule acts as a zwitterion, showing 
low lipophilicity and is hence impermeable of biological membranes 
(Huxtable, 1992). Taurine is not believed to be incorporated into proteins as 
no aminoacyl tRNA synthesase has been found (Lambert et al., 2015). 
Taurine is highly abundant in excitable and secretory tissues (Huxtable, 
1989).  
As early as 1915 taurine was proposed to act as an osmoregulator, which was 
later confirmed by several investigators (Huxtable, 1992). It is now known 
that one of the physiological functions of taurine is to act as an 
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osmoregulatory agent, both within and outside of the CNS, as the flow of 
taurine over cell membranes mostly are driven by changes in the external 
osmolarity (Huxtable, 1992; Oja & Saransaari, 1996). A reduction in external 
osmolarity increases taurine efflux from both astrocytes and neurons, as part 
of re-equilibration of osmotic pressure (Solis et al., 1988; Oja & Saransaari, 
1992; Pasantes-Morales et al., 1993; Moran et al., 1994b; Vitarella et al., 
1994; Oja & Saransaari, 1996; Deleuze et al., 1998). Furthermore, 
microdialysis performed in the rat hippocampus (Lehmann, 1989) or nAc 
(Quertemont et al., 2003) showed that perfusion of a hypoosmotic medium 
increased extracellular taurine levels, and taurine-deficient cultured 
astrocytes showed impaired cell volume regulation (Moran et al., 1994b). In 
1973, Huxtable and Bressler proposed taurine to act as a membrane stabilizer 
as they demonstrated that addition of the amino acid to the cell medium 
slowed the rate of loss of Ca2+ transport and ATPase activities of 
sarcoplasmatic reticulum from rat skeletal muscles caused by phospholipase 
C (Huxtable & Bressler, 1973). Since then, taurine has been shown to have 
antioxidative effects, for example by preventing cellular damage caused by 
reactive oxygen species such as nitrogen oxide (Gordon et al., 1986; 
Gurujeyalakshmi et al., 2000), and ozone (Banks et al., 1992), as well as by 
maintaining efficient mitochondrial protein translation (Schaffer et al., 2009). 
Taurine also modulates Ca2+-dependent processes. This is most evident in the 
heart where taurine is positively inotropic in hearts exposed to 
subphysiological concentrations of Ca2+ and negatively inotropic when 
exposed to supraphysiological concentrations of Ca2+. These positive and 
negative inotropic effects parallel the effects of taurine on Ca2+ binding to 
cardiac cell membrane and Ca2+ entry through the calcium channel 
(Huxtable, 1992). Taurine is also involved in physiological processes such as 
lung function and development (Lambert et al., 2015). For example in the 
lung, taurine potentiates relaxation of precontracted airway smooth muscle 
cells through GABAARs (Gallos et al., 2012), and the offspring of cats fed 
taurine-free diet, display abnormal hind leg development, smaller brain- and 
body-weight, degeneration or abnormal development of the retina and visual 
cortex (Sturman, 1991).  
In the adult human, taurine is synthesized predominantly in the liver but also 
to some extent in the brain (Stipanuk et al., 2002; Stipanuk, 2004). However, 
for newborns dietary taurine is essential as children under the age of one 
years old are not able to synthesize sufficient amounts (Lambert et al., 2015). 
Taurine is synthesized from cysteine via cysteine dioxygenase to 
cysteinsulfonate, which is converted to hypotaurine by cysteinsulfinate 
decarboxylase. Hypotaurine is then oxidized to taurine (Stipanuk et al., 
2002). A minor synthesis pathway of taurine occurs via degradation of 
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coenzyme A to cysteamine, which is then oxidized to hypotaurine by 
cysteamine dioxygenase (Dominy et al., 2007). The daily human intake of 
taurine varies depending on which food that is consumed, as the amount of 
taurine varies greatly among different kinds of food. Meat and fish contain 
high amounts of taurine whilst a vegan diet is almost taurine deficient 
(Laidlaw et al., 1990), resulting in individuals consuming a strict vegan diet 
to have decreased plasma taurine levels (14-22% lower) and 2-3 times less 
amount excreted in urine compared to omnivores (Rana & Sanders, 1986; 
Laidlaw et al., 1988). As taurine is not metabolized in the mammal it is 
excreted via the urine or conjugated to bile acids, which are secreted via 
faeces (Huxtable, 1992).  
As mentioned above, taurine is impermeable of biological membranes. 
Consequently, uptake of taurine into the cell is performed via the high-
affinity, low capacity, Na+ and Cl--dependent taurine transporter (TauT) and 
the high capacity, proton-coupled but Na+-independent β-amino acid 
transporter PAT1. Contrary to uptake into cells, taurine is released via 
volume-insensitive or volume-sensitive pathways. During isotonic conditions 
taurine, in low amounts, leaks from the cell to the extracellular environment 
through a volume insensitive pathway (Lambert et al., 2015). By which 
mechanisms this occurs is not fully understood although it has been proposed 
that the TauT is responsible for this by working in reverse, releasing taurine 
from the cell (Lambert & Hoffmann, 1993). This is not likely however, due 
to the low cellular Na+ concentration (Poulsen et al., 2010). The release of 
taurine via the volume-sensitive pathway occurs within minutes following 
hypotonic exposure and involves the volume regulated anion channel 
(VRAC) (Lambert et al., 2015; Jentsch, 2016). 
VRACs are anion channels expressed in vertebrate cells. They are activated 
by cell swelling and regulate cell volume by the efflux of Cl- and organic 
solutes such as taurine (Hoffmann et al., 2009; Jentsch, 2016; Strange et al., 
2019). When osmotic cell swelling was introduced by removal of sucrose 
from the external bath solution, the VRAC current was activated following an 
increased cell-volume of 10%. Inactivation of the VRAC current can be 
obtained by increasing the external bath osmolality (Bond et al., 1999; 
Strange et al., 2019). Besides cell swelling, VRACs can also be activated by 
other factors, such as reactive oxygen species (Shimizu et al., 2004; Liu et 
al., 2009; Deng et al., 2010), and by a reduction in intracellular ionic strength 
(Cannon et al., 1998; Nilius et al., 1998). In the brain, VRACs not only 
constitute a pathway for taurine release, but have also been found to release 
aspartate and glutamate (Akita & Okada, 2014; Mongin, 2016).  
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Within the CNS, taurine acts as an agonist at the GlyR (Curtis et al., 1968; 
Haas & Hosli, 1973; Okamoto & Sakai, 1980; Taber et al., 1986). In addition 
to taurine, glycine, beta-alanine and GABA are also capable of activating the 
receptor, with the following order of potency: glycine, beta-alanine, taurine 
and GABA (Lewis et al., 2003; Pless et al., 2007). Differences in response of 
these agonists depend on the expression system used, as glycine, beta-alanine 
and taurine act as full agonists in HEK293 cells and as partial agonists in 
Xenopus laevis oocytes (De Saint Jan et al., 2001; Lewis et al., 2003). 
Taurine also acts as an agonist at the GABAAR (Haas & Hosli, 1973; 
Okamoto & Sakai, 1980; Taber et al., 1986; Bureau & Olsen, 1991), and as 
an antagonist at the NMDAR (Kurachi et al., 1983; Lehmann et al., 1984). 
Binding of taurine to the GABABR has also been shown but with undefined 
functional effects (Kontro et al., 1990; Kontro & Oja, 1990). A taurine 
receptor has been proposed to exist, however this protein has not yet been 
defined (Girard et al., 1982; Okamoto et al., 1983a; Wu et al., 1992; Frosini 
et al., 2003). Whether taurine fulfills the criteria to acts as a neurotransmitter 
or not within the CNS is a matter of debate. 
Interactions between taurine and ethanol in the CNS 
In one of the first studies examining the effect of taurine on ethanol-induced 
behavior, Arvid Carlsson and colleagues showed that taurine influenced 
motor behavior during ethanol treatment (Garcia de Yebenes Prous et al., 
1978). Since then, several studies have shown taurine to have the ability to 
affect ethanol-induced behavior. Taurine has been shown to both reduce and 
enhance ethanol-induced locomotion (Aragon et al., 1992) and sedation 
(McBroom et al., 1986; Ferko & Bobyock, 1988). Administration of taurine 
enhanced conditioned place aversion produced by a low dose of ethanol, 
blocked conditioned placed aversion produced by an intermediate dose, and 
had no effect on a higher dose of ethanol (Aragon & Amit, 1993). 
Quertemont and co-workers have shown that oral taurine supplementation 
causes CPP at a low dose of ethanol, as compared to non-taurine 
supplemented animals. They suggested this finding to involve the interaction 
of taurine and dopamine in the mesolimbic dopamine system. As both taurine 
and low doses of ethanol increase dopamine levels, a simultaneous 
administration of these two substances may induce preference. They also 
demonstrated reduction of ethanol-induced aversion at a high ethanol dose by 
taurine supplementation, and proposed that this may be explained by the 
ability of taurine to maintain intracellular calcium homeostasis. Thus, the 
administration of taurine together with ethanol may restore any ethanol-
induced changes in intracellular calcium, and will reduce any aversive 
behavioral effects (Quertemont et al., 1998b). That taurine would reduce the 
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aversive effects of ethanol is further supported by a taurine-induced reduction 
of blood and liver acetaldehyde-concentrations caused by ethanol (Watanabe 
et al., 1985). These studies indicate that the ability of taurine to modify the 
rewarding, aversive as well as behavioral effects of ethanol to be dependent 
on dose and treatment time of the drugs. Furthermore, taurine has also been 
shown to reduce ethanol consumption in rats. Acute systemic administration 
of taurine (50, 100 or 200 mg/kg) 15 minutes prior ethanol or water intake 
reduced ethanol consumption by approximately 25-40%, but did not 
influence ethanol intake at a dose of 10 mg/kg taurine. The water 
consumption was also reduced at the dose of 200 mg/kg, indicating a general 
influence on fluid intake at this dose (Olive, 2002). 
In the first in vivo microdialysis study demonstrating an ethanol-induced 
increase of taurine in the nAc the aim was to investigate the effect of alcohol 
on the excitatory amino acid glutamate and two inhibitory amino acids, 
GABA and taurine. It was found that extracellular taurine levels increased 40 
minutes after a systemic injection of 2 or 3 g/kg ethanol. The investigators 
speculated that the increase in taurine was due to compensatory mechanism, 
such as cell membrane stabilization and osmoregulation, to counteract the 
effects of acute ethanol on cell membrane, and on cell volume (Dahchour et 
al., 1994). Subsequently, several microdialysis studies demonstrated 
increased extracellular accumbal levels of taurine in a dose-dependent 
manner after systemic ethanol administration (De Witte et al., 1994; 
Dahchour et al., 1996; Olive et al., 2000; Quertemont et al., 2003; Smith et 
al., 2004; Ericson et al., 2011), and during local administration of ethanol in 
the nAc (Adermark et al., 2011a; Ericson et al., 2017). Increased 
extracellular taurine levels in the nAc were also shown during operant 
ethanol self-administration, where the increase in taurine was positively 
correlated with ethanol dose (Li et al., 2008), and greater in FIE (forced 
intermittent ethanol) rats compared to control rats (Li et al., 2010). The 
magnitude of the taurine response after acute ethanol treatment also appears 
to be influenced by the level of ethanol-sensitization (as measured by 
locomotor activity), as low sensitized mice showed higher extracellular 
accumbal levels of taurine after an acute ethanol challenge than high 
sensitized mice (Nashed et al., 2019). 
We previously demonstrated that taurine is required for ethanol-induced 
dopamine increase (Ericson et al., 2011). This study suggested a functional 
link between taurine and dopamine in response to ethanol. An interaction 
between taurine and dopamine in the brain is further supported by a 
behavioral study showing that endogenous brain levels of dopamine are 
increased in rats injected intracerebroventriculary with taurine, and that 
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dopamine depletion induced by alpha methyltyrosine is retarded by taurine 
(Garcia de Yebenes Prous et al., 1978). 
There are studies indicating a genetic influence on ethanol-induced levels of 
taurine in the nAc. Rats genetically bred for low alcohol sensitivity showed a 
delayed increase in taurine after systemic ethanol administration as compared 
to high alcohol sensitive rats, which response was similar to those of regular 
Wistar rats (Dahchour et al., 2000). Differences have also been shown 
between Sardinian ethanol-preferring and Sardinian ethanol-non-preferring 
rats, where ethanol-induced taurine release in the alcohol-preferring rats was 
lowered by comparison to the ethanol-non-preferring rats (Quertemont et al., 
2000). Mice, lacking the epsilon isoform of protein kinase C, are behaviorally 
and biochemically “supersensitive” to ethanol and other allosteric modulators 
of the GABAAR, and display increased endogenous extracellular levels of 
taurine in the nAc. In these mice, ethanol fails to increase accumbal taurine as 
well as dopamine levels (Olive et al., 2000). Furthermore AUD patients may 
have reduced endogenous levels of taurine (Majumdar et al., 1983), if this is 
a cause or consequence of excessive alcohol intake, or a consequence of 
malnutrition is still to be determined.  
It is clear that taurine and ethanol interact in the CNS both on a behavioral 
and a biochemical level. As taurine has osmoregulatory effects, and as 
ethanol induces cell swelling, we have proposed that taurine is released from 
the cell into the extracellular environment due to osmoregulation (Adermark 
et al., 2011b; Ericson et al., 2011). However, more studies are needed to 
clarify the mechanisms involved.  
Energy drinks and their interaction with ethanol 
Energy drinks first appeared around 1960 in Asia and Europe, although it 
was the introduction of “Red Bull” in 1987 in Austria and in 1997 in the 
United States that really started the trend of an aggressive marketing of these 
drinks. Since then, the market has grown fast with hundreds of brands 
worldwide (Reissig et al., 2009). Energy drinks usually contain high amounts 
of caffeine, taurine, glucoronolactone, glucose, vitamins and herbal 
supplements (McLellan & Lieberman, 2012), and are often marked to 
increase physical and mental attention, endurance and performance as well as 
weight loss. Children, adolescents and young adults consume the majority of 
energy drinks and adverse health effects have been reported when using these 
products (Seifert et al., 2011). The immature and developing brain is 
vulnerable and may be influenced by both caffeine and taurine (Curran & 
Marczinski, 2017). Much focus has been put on the effects of energy drinks 
Lisa Ulenius 
19 
on cardiovascular function as these drinks contain high amounts of caffeine. 
It is known that acute caffeine moderately can increase blood pressure and 
heart rate (Mesas et al., 2011; Higgins & Babu, 2013), which may not be 
harmful in healthy adults. However, in the small body of a child or 
adolescent, with no developed tolerance to simulative substances, these 
effects can be significant (Curran & Marczinski, 2017). Therefore, several 
countries have at times banned the sales of energy drinks to minors (Ragsdale 
et al., 2010; Seifert et al., 2011). In the USA, as energy drinks are sold as 
food supplements and not as food (FDA), the product does not undergo the 
same regulatory processes and the amount of ingredients in energy drinks are 
not always known. This is alarming, considering the high intake of energy 
drinks among the young population. In Sweden, the total amount of caffeine 
in each energy drink has to be disclosed. However, there is no limit for the 
amount of taurine (Svenska Livsmedelsverket).  
Besides intake of energy drinks alone, it is popular to consume them together 
with alcohol (Oteri et al., 2007; Marczinski et al., 2011; Seifert et al., 2011). 
There are several reports indicating that this consumption is associated with 
risks. In 2008, O’Brien and colleagues reported that college students 
consuming the combination of alcohol mixed with energy drinks (AmED) 
compared to students drinking alcohol alone, consumed more alcohol on each 
drinking session and had twice as many episodes of weekly drunkenness. The 
increased alcohol consumption alone would increase the risk of 
violence/accidents and the development of AUD even without any direct 
pharmacological contribution of the ingredients of the energy drinks. It was 
further reported that the students consuming AmED had an increased risk of 
emergency room visits, driving intoxicated or riding a car with an intoxicated 
driver, as well as being engaged in undesired sexual activity (O'Brien et al., 
2008). Consuming AmED also attenuates some of the self-reported 
symptoms of alcohol intoxication, such as headache, weakness, and 
perception of motor coordination. However, objective measures like blood 
alcohol concentration, visual reaction time and motor coordination was not 
reported to be changed (Ferreira et al., 2006). People’s consumption of 
AmED would suggest an impaired ability to assess both their own and others 
levels of intoxication which would put both themselves and others at risk. 
Which ingredients that are responsible for these risks and the mechanisms of 
action underlying the effects are not clear. Subsequently, increased frequency 
in alcohol intake and consumption of larger amounts at each drinking session 
among AmED users, compared to those drinking alcohol alone, was shown to 
increase the risk for alcohol-related harm and the development of AUD (Price 
et al., 2010; Arria et al., 2011). It has also been shown that weekly or daily 
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energy drink consumption (note that this is not in combination with alcohol) 
is strongly associated with AUD (Arria et al., 2011).  
Taurine and caffeine as pharmacological active substances in energy drinks when 
combined with alcohol 
Caffeine and taurine are the two major ingredients in energy drinks, and in 
general one can (approximately 250 ml) contains 80 mg caffeine and 1000 
mg taurine (McLellan & Lieberman, 2012). A regular cup of coffee (150 ml) 
contains approximately 100 mg caffeine, and the daily intake of taurine for 
omnivores is about 120-130 mg (Svenska Livsmedelsverket 2019).  
When reviewing the literature much focus is on caffeine as the 
pharmacological active ingredient in energy drinks per se, as well as when 
combined with alcohol. Preclinical studies support an interaction of caffeine 
and ethanol as it has been shown that a systemic injection with caffeine 
increases voluntary ethanol intake (Kunin et al., 2000), promotes ethanol-
induced conditioned taste aversion (Kunin et al., 2001) and ethanol-induced 
locomotion (Hilbert et al., 2013) in rodents. The combination of caffeine and 
ethanol induced conditioned place preference in mice, although the 
combination produced no greater effect than ethanol alone (Hilbert et al., 
2013). A common target for ethanol and caffeine is the adenosinergic system. 
It has been proposed that ethanol increases extracellular levels of adenosine 
in vitro (Nagy et al., 1990; Krauss et al., 1993), and antagonism of adenosine 
A2 receptors (A2R) enhances or attenuates ethanol self-administration 
depending on the concentration of antagonists used (Arolfo et al., 2004). 
Furthermore, it has been suggested that A2R are involved in the development 
of goal-directed ethanol drinking in mice (Nam et al., 2013). Taken together, 
it has been hypothesized that ethanol exerts some of its behavioral effects by 
increasing extracellular levels of adenosine in the brain, with subsequent 
activation of adenosine receptors. As caffeine acts as a nonselective 
antagonist at adenosine receptors (Fredholm et al., 1999) this could be part of 
a pharmacological mechanistic explanation for the interaction of caffeine and 
ethanol. Interestingly, dopaminergic mechanisms have been suggested to 
mediate some of the behavioral effects of caffeine (Garrett & Griffiths, 
1997). A2-receptors and dopamine D2-receptors are co-expressed in neurons 
of the nAc where they functionally interact with each other (Ferre et al., 
1991; Morelli et al., 1995). Caffeine enhances dopaminergic activity, 
presumably by competitive antagonism at these A2-receptors and thereby 
removing the negative modulatory effects of adenosine on dopamine D2-
receptors (Garrett & Griffiths, 1997). This is interesting since ethanol is 
known to increase extracellular levels of dopamine in the nucleus accumbens, 
Lisa Ulenius 
21 
an effect associated with positive reinforcement (Di Chiara & Imperato, 
1988; Wise & Rompre, 1989; Spanagel, 2009).  
As we have proposed that taurine and ethanol are interconnected in the brain 
reward system (see the above section “Interactions between taurine and 
ethanol in the CNS”) we suggest that taurine could act as a pharmacological 
active ingredient in energy drinks when consumed together with alcohol. 
That both caffeine and taurine could have an impact on ethanol-induced 
behavior is further supported by the fact that administration of energy drink 
(containing caffeine and taurine) to mice reduces the depressant effects of 
ethanol and enhances ethanol-induced behavioral sensitization (Ferreira et 
al., 2004; Ferreira et al., 2013). 
Taurine and dopamine-related effects of ethanol 
22 
OBJECTIVES 
Furthering the knowledge about ethanol’s interaction with the brain reward 
system and especially it’s interplay with dopamine and taurine may provide 
knowledge important for the development of new pharmacotherapies against 
alcohol use disorder (AUD). The overall aim of this thesis was to investigate 
correlations between taurine and dopamine during ethanol exposure, with 
special emphasis on neurochemical effects in the nAc. 
The specific aims of the present thesis are the following: 
• To define the impact of voluntary ethanol intake on both 
endogenous levels, as well as ethanol-induced elevation of 
taurine and dopamine (Paper I) 
 
• To determine if repeated exposure to taurine affects 
neurochemical and/or behavioral responses to ethanol  
(Paper II) 
 
• To characterize the origin of ethanol-induced taurine release 
(Paper III) 
 
• To outline the modulatory role of energy drink constituents 
caffeine and taurine on ethanol-induced locomotor activity 
(Paper IV) 
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METHODOLOGY 
More detailed descriptions of the materials and methods employed in this 
thesis are to be found in the individual papers. Below follows a brief 
description, including reflections, of the different experimental 
methodologies used in the present thesis. 
Animals and animal models 
Animal models have been used in preclinical studies for decades as a way to 
shed light on and increase the understanding of normal, as well as 
pathological, conditions in humans. The use of rodents to elucidate 
behavioral, environmental and neuronal mechanisms underlying 
neuropsychiatric disorders, such as AUD, is especially suitable, as the 
translatability to humans appears good. This is due to the fact that several key 
brain regions are highly conserved between species, and the genome of 
rodents is approximately 90% similar to the human genome (Mullins & 
Mullins, 2004). In all of the studies that constitute this thesis, outbred rat 
(Wistar) and mouse (NMRI) strains were used, in order to somewhat mimic 
the genetic variation in the human population and thereby enhance the 
translatability to the human situation. All experiments presented in this thesis 
were approved by the Ethics Committee for Animal Experiments, 
Gothenburg, Sweden. 
In the microdialysis studies (paper I, II and III), for the intermittent ethanol 
consumption study (paper I), for the designer receptor exclusively activated 
by designer drugs (DREADDs)-experiments, for gene expression analysis 
(paper II) and for blood and cerebrospinal fluid (CSF) analysis (paper I and 
II) adult, male Wistar rats (Taconic, Denmark; Janvier Labs, France; Envigo 
Germany) were used. These rats were selected as our research group has an 
extensive experience with regard to neurochemistry and behavior displayed 
by this strain.  
The Wistar rat is also commonly used in animal studies within the field of 
addiction, and is a foundation stock for several rat lines bred for high and low 
voluntary ethanol intake (Palm et al., 2011). Moreover, it has been shown 
that the Wistar rat strain displays a high ethanol intake with pharmacological 
relevant blood ethanol concentrations when the intermittent ethanol 
consumption model used in this thesis is applied (Simms et al., 2008). 
Nevertheless, studies report different results in ethanol intake in Wistar rats, 
emphasizing the vendor as an important parameter (Palm et al., 2011). For 
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locomotor activity measurements (paper IV) adult, male NMRI (Charles 
River, Germany) mice were used instead of rats, since rats rarely display an 
increase of locomotion after acute ethanol administration (Linakis & 
Cunningham, 1979; Masur et al., 1986; Criswell et al., 1994; Chuck et al., 
2006; Brabant et al., 2014). NMRI mice were selected as it has been shown 
that this strain shows robust ethanol-induced locomotion and accumbal 
dopamine increase (Engel et al., 1974; Engel et al., 1988; Jerlhag et al., 
2009). All of the animals were allowed at least one week of acclimatization 
to the animal facility before any experiments were initiated. For the entire 
duration of the experiments, animals had access to standard rat feed and tap 
water ad libitum 
Notably, Wistar rats were sometimes purchased from different vendors, 
which was due to the fact that Taconic, Denmark, stopped their marketing of 
Wistar rats. Therefore, we had to screen a number of Wistar rats from 
different suppliers in the microdialysis set-up. The rats were administrated 
ethanol and nAc taurine as well as dopamine were monitored. Unfortunately, 
we experienced that Wistar rats from the different vendors differed with 
respect to endogenous levels of taurine in the nAc. Even their body weight 
and anatomical features were different. The differences observed might be 
due to genetic variation, but also by the fact that different laboratory diets 
were used by the vendors. Furthermore, supplier-dependent differences have 
been shown in intermittent ethanol intake as well as in response to naltrexone 
treatment in Wistar rats (Momeni et al., 2015). Nevertheless, their accumbal 
dopamine response after ethanol or ethanol in combination with taurine was 
the same. In this thesis, rats from different vendors were applied in the 
studies included in paper II and III. The following actions were taken to 
minimize the impact on the results: rats from the different vendors in each 
experiment were compared with respect to parameters important for the 
outcome, such as endogenous taurine and dopamine levels, the ethanol- 
induced taurine and dopamine increase, and the behavior of the animal was 
observed. Data presented in this thesis should not be significantly affected by 
the use of different vendors. However, it is not possible to completely 
exclude a potential impact and therefore, in general, it is preferable to as far 
as possible use rats from the same vendor. This also puts focus on the 
inherent heterogeneity among Wistar rats and the possibility to utilize their 
different attributes in study design. 
As mentioned above, animal models constitute an important tool in the study 
of pathological processes underpinning AUD. However, addiction is a 
multifactorial disease and there is unfortunately not one single animal model 
that fully reflects the complex clinical picture of AUD. Therefore, several 
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different models are used to reflect the divers aspects, including relapse, cue-
induced craving, sensation of reward and withdrawal symptoms (Spanagel, 
2000). How well an experimental animal model reflects a certain human 
condition is termed validity. There are different forms of validity, such as 
face validity, construct validity and predictive validity. Face validity refers to 
how well the symptoms/behaviors observed in the animal model reflect those 
in the human medical condition. Construct validity refers to how similar the 
underlying pathophysiology in the animal model is to that in humans. Finally, 
predictive validity refers to how well the animal model predicts the effects of 
manipulations or treatments on the human condition. Since one experimental 
animal model seldom reflects the whole human medical condition, it is of 
great importance to cautiously select the model that is best suited for 
challenging the hypothesis in question, and often several different models are 
needed. The validity of the different models used in this thesis will be 
discussed further in the following subchapters.  
In pre-clinical studies, including alcohol research, the use of male animals 
largely exceeds females. Importantly, sex differences in alcohol intake and 
ethanol-induced increase in nAc dopamine levels have been demonstrated in 
rodents (Lancaster & Spiegel, 1992; Blanchard et al., 1993). Sex differences 
in alcohol use are also present in the human population (Erol & Karpyak, 
2015). Thus, the same result cannot be expected in the opposite sex and 
studies including both sexes are needed. In pre-clinical studies employing 
female animals it is of importance to take into consideration the potential 
influence of the estrous cycle, as it has been demonstrated that alcohol intake 
varies in females depending on their estrous cycle (Forger & Morin, 1982). 
Traditionally in our laboratory male rodents have been used, and have 
therefore also been used in the studies of the present thesis. However, with 
regards to the above mentioned reasons we have started to include female 
animals in our studies. These studies are only at a preliminary stage and 
hence not included in this thesis.  
Drugs and chemicals 
Ethanol 
For the intermittent drinking paradigm, 95% ethanol was diluted in tap water 
to a 20% ethanol solution. For all i.p. injections, 95% ethanol was diluted in 
0.9% NaCl to a concentration of 15%. For blood and CSF analysis, ethanol 
was administrated 2.5 g/kg, i.p. For the locomotion study in paper II, rats 
were administrated a lower dose of ethanol (0.25g/kg, i.p.) to avoid a sedative 
effect. During the different microdialysis studies, rats were administrated 2.5 
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g/kg or 2.75 g/kg i.p. In microdialysis experiments where ethanol was 
administrated by local perfusion via the microdialysis probe, 95% ethanol 
was diluted in Ringer’s solution, which contains (in mmol/l): 140 NaCl, 1.2 
CaCl2, 3.0 KCl and 1.0 MgCl2, to a concentration of 300mM. During 
locomotor activity measurements, mice were administrated 1.75, 2.5 or 3.25 
g/kg ethanol, i.p. In paper I, when ethanol was consumed orally by the rats, 
20% ethanol solution was used as this concentration has been proven to 
establish pharmacologically relevant ethanol blood concentrations in the 
intermittent voluntary ethanol consumption model (Simms et al., 2008). The 
dose of 2.5 g/kg ethanol for i.p. administration was chosen as this is a high 
dose, yet not making the rat unconscious but still inducing measurable 
dopamine levels. The concentration of ethanol used for perfusion, via the 
microdialysis probe, in the nAc was based on a dose-response study 
performed in our laboratory (Ericson et al., 2003), this high, yet 
pharmacologically relevant concentration, was chosen as it increases 
dopamine levels in the nAc to approximately the same extent as 2.5 g/kg 
ethanol i.p. In paper IV, for systemic administration of ethanol to mice, two 
moderate doses (1.75 and 2.5 g/kg) were used has these have been shown to 
increase locomotor activity in mice (Carlsson et al., 1974; Liljequist, 1991; 
Blomqvist et al., 1994; Hilbert et al., 2013; Vallof et al., 2017). A higher dose 
(3.25 g/kg), with sedative effects (Hilbert et al., 2013) was used to account 
for the possibility that caffeine and/or taurine may diminish the sedative 
effects of ethanol. 
Taurine 
For all of the experiments, taurine was dissolved in 0.9% NaCl. The rats were 
given taurine 0.25 g/kg, i.p. for 10 days or intermittently for 15 days, or as an 
acute treatment during microdialysis experiments, or for blood and CSF 
analysis. For locomotor activity studies, mice were administrated taurine 30, 
60, 300 or 600 mg/kg, i.p. The dose of 0.25 g/kg for systemic administration 
was used as it has been demonstrated to increases taurine levels in plasma as 
well as in the extracellular fluid of the hippocampus (Lallemand & De Witte, 
2004). In paper IV, four different doses of taurine was used, as it has been 
demonstrated that either low or high doses of taurine alone or in combination 
with ethanol may affect locomotor activity (Aragon et al., 1992; Ginsburg & 
Lamb, 2008; Whirley & Einat, 2008). 
Caffeine 
Caffeine was dissolved in 0.9% NaCl. Mice were given caffeine 15 mg/kg, 
i.p. intermittently for 18 days. During locomotor activity measurements, mice 
were administrated 1, 5, 15 or 30 mg/kg caffeine i.p. These doses were used 
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because the threshold dose for caffeine-induced locomotor activity has been 
demonstrated to be approximately 3 mg/kg, and a maximum effect to be 
present at 20-30 mg/kg (Buckholtz & Middaugh, 1987; Hsu et al., 2009; 
Hilbert et al., 2013). The lowest dose of caffeine was chosen to account for 
possible additive effects when administrated together with ethanol and/or 
taurine. 
Clozapine-N-oxide 
The DREADD ligand Clozapine-N-oxide dihydrochloride (CNO) was 
dissolved in 0.9% NaCl and administrated 3 mg/kg, i.p, a dose within the 
recommended dose interval (Roth, 2016). 
Tetrodotoxin 
The Na+ channel blocker tetrodotoxin (TTX) was dissolved in Ringer’s 
solution to a concentration of 1 µM, and administrated by reversed 
microdialysis. This concentration was used as it has been shown to decrease 
taurine levels in the hypothalamus (Singewald et al., 1993).  
Fluorocitrate 
The glial metabolic inactivator dl-fluorocitrate was dissolved in Ringer´s 
solution to a concentration of 25 µM, and administrated by reversed 
microdialysis. A dose-response study performed in our laboratory showed 
that a dose of 25 µM was the highest dose without impact on the dopamine 
levels per se, and without negative behavioral effects (data not shown). The 
chosen dose decreased extracellular levels of glutamine by approximately 
60% indicating intended effects on glial cells (data not shown). 
DCPIB  
The VRAC inhibitor DCPIB (4-(2-Butyl-6-7-dicholro-2-cyclopentyl-indan-1-
on-5-yl) oxobutyric acid) was dissolved in dimethyl sulfoxide (DMSO) 
(0.4% of the final solution) and diluted in Ringer’s solution to a 
concentration of 100 µM, and administrated by reversed microdialysis. This 
dose of DCPIB was used as it has previously been shown to decrease the 
ischemia-induced release of aspartate and glutamate in the microdialysis 
setup (Zhang et al., 2008). In an attempt to increase the concentration of 
DCPIB, to enhance the pharmacological outcome of the experiment, the 
concentration of DMSO had to be increased to a point where DMSO alone 
had a major impact on both taurine and dopamine. This approach was 
concluded to be futile.  
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The different routes of administration were chosen to accommodate the 
specific aim. For mechanistic studies, where a local effect of the drug is 
desirable, local administration of the drug via the microdialysis probe was 
applied. Taurine, caffeine and ethanol were systemically administrated by i.p. 
injections to mimic the human situation where the drug is ingested orally, 
while at the same time controlling the amount of drug delivered. When a 
drug, aiming for specific targets is applied, its degree of specificity is 
important to take into consideration. Clearly, a high specificity is desirable in 
order to abate side effects, which can interfere with the results. Furthermore, 
the specificity of the drug generally decreases with increased dose.  
Behavior 
In this thesis two different behavioral animal models are used, which both 
utilize the ethological behavior of the animal: locomotor activity and 
voluntary drug intake in an intermittent drinking paradigm. 
Locomotor measurements and behavioral sensitization 
Behavioral sensitization and locomotor measurements were assessed in paper 
II in order to study the impact of repeated taurine administration on the acute 
effects of ethanol, and in paper IV to study the effects of the combination of 
caffeine and taurine on ethanol-induced locomotor activity in naïve and 
caffeine experienced animals. 
Behavioral sensitization is a phenomenon where the same dose of a drug 
produces an increased response after repeated exposure. The increased drug-
induced behavioral response is suggested to reflect neuroadaptations induced 
by repeated drug administration (Robinson & Berridge, 1993). Consequently, 
the model of behavioral sensitization is used in paper II and IV to study 
potential adaptations linked to dopamine related behavior after repeated 
taurine (0.25 g/kg, i.p.) administration for ten days (paper II) or an 
intermittent caffeine treatment regimen during fifteen days with a total of 
eleven injections (paper IV). The stimulatory effect of the drug was measured 
on the first and last day of the treatment periods. 
The measurement of rodents’ spontaneous activity is frequently used for 
studying the development of behavioral sensitization and drug-induced 
behavioral effects related to the brain reward system. This is based on the 
ability of ethanol, like most drugs of abuse, to increase locomotion in 
rodents, which is suggested to be related to ethanol-induced activation of the 
mesolimbic dopamine system (Carlsson et al., 1974; Liljequist et al., 1981; 
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Wise & Bozarth, 1987; Engel et al., 1988). Therefore, locomotor stimulatory 
effects induced by acute drug treatment in drug naïve as well as in sensitized 
animals were monitored in paper II and IV. The open field arena used for 
these measurements consists of a two-layer grid of infrared beams, which 
makes it possible to measure both horizontal and vertical activity. Activity is 
registered when the animal’s movement causes beam breaks. All animals 
were habituated to the test box before acute drug challenge, in order to 
abolish impact of the rodents’ innate exploratory behavior to novel 
environment with the drug-induced effects. In both paper II and IV were the 
stimulatory effect analyzed with regards to locomotor activity (horizontal 
beam breaks) and in paper II it was also analyzed with regards to rearing 
activity (vertical beam breaks). 
It is considered that behavioral sensitization is a valid model for studying 
neuroadaptations induced by repeated drug intake (Steketee & Kalivas, 
2011). Although taurine and caffeine are not usually referred to as classic 
drugs of abuse (e.g. ethanol, nicotine, amphetamine), in our studies 
behavioral sensitization was found to be induced, which indicates some kind 
of neuronal adaptations. One important aspect of the behavioral sensitization 
model and the measurement of locomotion is that, normally and in this thesis, 
drug administration occurs in a non-voluntary manner. This is in contrast to 
the human situation where initial drug intake is largely a voluntary behavior. 
It is important to keep in mind that locomotor activity should be regarded as 
an approximation of dopaminergic neurotransmission and not as a direct 
measurement. To further elucidate the mechanism of action it is necessary to 
add other methods such as microdialysis, electrophysiology and/or 
immunohistochemistry. However, the method is useful as a first step in 
exploring a hypothesis (as was done in paper IV), as it is relatively simple.  
Intermittent ethanol consumption 
In paper I the intermittent access 20% alcohol two-bottle-choice drinking 
paradigm was used in order to study tentative divergences between high and 
low ethanol consuming rats with regards to baseline, as well as ethanol-
induced, taurine and dopamine levels in the nAc.  
Voluntary ethanol consumption in rats is frequently used to model human 
alcohol intake and AUD, providing a valuable tool for studying 
neurochemical and behavioral changes induced by high ethanol intake over 
time. The intermittent access 20% alcohol two-bottle-choice drinking 
paradigm used in paper I has been shown to induce high and stable ethanol 
intake and pharmacologically relevant blood ethanol concentrations in Wistar 
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rats. Furthermore, good predictive validity has been demonstrated as 
treatment with acamprosate as well as naltrexone reduce alcohol intake in this 
model (Simms et al., 2008). The paradigm is based on voluntary drug intake 
as rats are allowed to drink in their home cage and choose when and how 
much to drink. In addition to one water bottle, the animals are given one 
bottle of alcohol for three 24-hour sessions per week. As rats are nocturnal 
animals and drink more during the dark phase, the alcohol is presented to the 
rats in the beginning of the dark cycle. This paradigm, as opposed to a 
continuous access paradigm, consists of repeated cycles of drinking and 
abstinence, which has been shown to increase voluntary alcohol intake (Wise, 
1973). Besides inducing a high consumption, this model reflects the human 
drinking pattern, in terms of a voluntary and intermittent consumption. 
During the entire experiment, rats are provided regular rat feed ad libitum and 
their consumption is monitored in order to exclude alcohol intake due to 
calorie loss. Furthermore, the concentration of alcohol used is of importance 
for the results. With low concentrations the taste is mild and sweet and 
becomes aversive with very high concentrations. However, with low 
concentrations there is a risk of pharmacological irrelevance as the amount of 
fluid ingested by the animal is limited by physical constrains (Sanchis-Segura 
& Spanagel, 2006). Generally, rats prefer lower concentrations of ethanol 
(Sanchis-Segura & Spanagel, 2006; Palm et al., 2011). However there is an 
individual variability as some rats will chose higher concentrations (Palm et 
al., 2011). A concentration of 20% alcohol has been shown to be preferable 
(Simms et al., 2008). A disadvantage with this method is that in order to 
monitor individual intake, the animals are normally single-housed. As 
rodents are gregarious animals this has a negative impact for their wellbeing 
and might thereby influence the results.  
Biochemical measurements 
In this thesis, samples from blood, CSF and accumbal extracellular fluid were 
sampled and analyzed by high performance liquid chromatography (HPLC) 
in order to measure levels of dopamine and amino acids, mainly taurine. 
Samples of the extracellular fluid were obtained by performance of in vivo 
microdialysis in the rat nAc.  
In vivo microdialysis 
In 1974, Ungerstedt and co-workers first described the method of in vivo 
microdialysis, which allows sampling of extracellular substances such as 
neurotransmitters and amino acids, in awake freely moving animals 
(Ungerstedt & Pycock, 1974). Via the implanted microdialysis probe, the 
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technique also enables delivery of drugs to specific brain regions, so called 
reversed microdialysis. Both types of microdialysis were applied in this 
thesis. In paper I, II and III this technique was used to quantify extracellular 
levels of taurine and dopamine in the nAc. Also other amino acids were 
detected when desirable. Wistar rats were used for all of the microdialysis 
experiments.  
In brief, two days before the microdialysis experiment, a probe with a semi-
permeable membrane is implanted into the brain region of interest. The active 
space of the membrane enables passive diffusion of solutes along its 
concentration gradient from the extracellular space into the probe or vice-
versa. On the day of microdialysis experiment, the probe is perfused with an 
artificial cerebrospinal fluid (Ringer’s solution), which may contain drug for 
appropriate pharmacological manipulations, and is then sampled from the 
outlet of the probe and analyzed by HPLC (fig. 2). 
Figure 2.  Descriptive 
image of the in vivo 
microdialysis set-up. A 
probe with a semi-
permeable membrane 
enables molecules to 
diffuse (along its 
concentration gradient) 
from the extracellular 
space into the probe or 
vice versa, from which the 
fluid is sampled and 
analyzed by high 
performance liquid 
chromatography (HPLC). 
Image by Julia Morud 
Lekholm; Nicotine 
sensitization and the 
effects of extended 
withdrawal, Doctoral 
thesis. 
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advantage with the technique is that each animal can serve as its own control, 
thereby reducing the number of subjects (Li et al., 2006). The are several 
different modifications available in order to optimize the outcome, such as 
sampling rate, the membranes’ molecular cut-off, flow rate of the perfusate 
and length of the active space. In the set-up used in this thesis, the sampling 
rate is set to every 20th minute. This rather slow sampling rate is commonly 
applied, as it is necessary for obtaining sufficient volume of fluid and 
concentration of solute needed for HPLC analysis. Consequently, the time-
resolution is low and fast events like burst firing of dopamine neurons are not 
possible to detect with this technique. For this electrophysiological 
recordings or in vivo voltammetry may be used. However, in vivo 
microdialysis is suitable for elucidating effects after chronic systemic 
treatment, (e.g. the drinking paradigm used in paper I, repeated taurine 
treatment used in paper II), or pharmacological manipulations (paper III) on 
neurotransmission, as well as showing good predictive validity. Furthermore, 
the possibility to implant more than one probe to the same animal enables 
manipulations and measurements of different brain areas simultaneously 
making the technique a powerful tool for studying neural circuits. Another 
aspect to take into consideration is the excovery (the concentration of drug in 
target tissue) and recovery (the amount of solute that is diffusing from the 
tissue to the probe) of the probe. Both vary due to the cut-off of the 
membrane, perfusion rate and intrinsic properties of the solute, e.g. pH, 
molecular weight, shape and polarity. Insertion of the probe will also have a 
pronounced impact as gliosis will occur in the surrounding tissue (Norton et 
al., 1992) and the surgery may cause mechanical damage and blood clots. To 
give the animal sufficient amount of time to recover after the surgery and to 
avoid a substantial amount of gliosis, the microdialysis experiment was 
initiated 48 hours after insertion of the probe. After completed experiment, 
brains were dissected and visually examined. Brains with incorrect probe 
placement and visible signs of error, e.g. bleeding, were excluded from data 
analysis. As discussed above, there are several factors that affect the 
excovery, which makes it difficult to select an appropriate concentration of 
drug for perfusion via the probe. Additionally, there is a concentration 
gradient in the tissue surrounding the probe with the highest excovery next to 
the probe. Results from our research group (unpublished data) have 
concluded that perfusion with 300 mM ethanol results in 60-70 mM in the 
surrounding tissue and the excovery rate is estimated to be approximately 24 
%. In order to avoid speculations and include uncertainties the concentration 
of the perfused drug is stated and not the assumed concentration in the tissue.  
In all of the studies that comprise this thesis, the coordinates for probe 
placement is aimed for the nAc core-shell borderline region, suggesting that 
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we are sampling in both the core and shell region. It has been shown that this 
area possesses a high density of GlyR (unpublished data), which we suggest 
are of importance for ethanol-induced dopamine release in the nAc. 
Furthermore, dopamine was increased in the nAc core-shell borderline but 
not in the core or shell during ethanol consumption (Howard et al., 2009). In 
our studies, coordinates for the core-shell borderline region have been proven 
successful when studying the dopamine elevating properties of ethanol after 
local (paper III), systemic (paper I, II and III) and oral administration (paper 
III).  
Blood and CSF sampling 
In paper I and II, blood and CSF were collected from naïve rats, rats with a 
history of ethanol consumption or rats systemically treated with ethanol or 
taurine to allow quantification of taurine in these fluids.  
Briefly, the animals were anesthetized, the heart exposed and blood collected 
from the left ventricle. Blood was drawn from the left and not right ventricle, 
as the outer wall of the left ventricle is thicker, this to reduce the risk of 
collapse of the ventricle. After the blood was withdrawn, the heart was 
punctured allowing the animal to bleed out. The cisterna magna of the animal 
was then immediately exposed and CSF sampled. The animal was drained 
from blood prior to the sampling of the CSF in order to avoid contamination 
of taurine from the blood into the CSF. CSF samples containing visual traces 
from blood were excluded from further analysis.  
HPLC analysis 
High performance liquid chromatography (HPLC) is a common technique 
used for separation, detection and quantification of molecules in a mixture. In 
the present thesis this technique is used for the analysis of accumbal 
extracellular samples obtained by microdialysis as well as samples from 
blood and CSF. 
Briefly, pumps use high pressure to press the sample, diluted in a mobile 
phase, through a column (stationary phase) filled with adsorbent material. 
Due to the intrinsic properties of each analyte, the interaction with the 
adsorbent material differ, leading to different flow rates and separation as 
they are pumped through the column. A detector generates a signal 
equivalent to the amount of the specific molecule enabling quantification. In 
this thesis, dialysate, blood and CSF samples were analyzed with regards to 
amino acids, primarily taurine. However, other amino acids as serine, 
glycine, glutamate and glutamine were also monitored when desirable. To 
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this end, a reversed phase-HPLC system consisting of a non-polar stationary 
phase and fluorescence detection was used. For the detection and 
quantification of dopamine in dialysate two different systems were used in 
parallel, one system utilized an ion exchange column and the other system a 
reversed phase column. As the dopamine molecule can be increased or 
decreased in its oxidation state, electrochemical detection was used for both 
systems. In order to identify and quantify amino acids as well as dopamine, 
internal standards were used. Four baseline samples for each animal were 
obtained before any drug challenge and an internal difference more than 
±10% was not accepted. Subsequent samples were calculated as percentage 
of baseline, which can be considered to reflect changes in volume 
transmission. However, absolute concentrations of extracellular analytes can 
also be obtained by using this technique, for instance when endogenous 
levels are of interest (paper I, II).  
The columns are expensive and easily degraded by particles in the sample or 
solvent and by irreversible binding of impurities. Thus, it is important that 
samples may not contain big particles, such as proteins and cells. Due to the 
semipermeable membrane of the microdialysis probe this is automatically 
avoided in the dialysate. Serum is obtained from the blood samples allowing 
detection of taurine by HPLC analysis. Although serum is the fraction of the 
blood containing the minimum numbers of particles, the serum as well as the 
CSF samples are deprotonated with trichloric acid and filtrated prior to 
analysis. The particle size of the material in the column influences the 
analysis. Small particle size gives better resolution because it provides a more 
uniform flow through the column, and because the distance through which 
solute must diffuse in the column and mobile phase is on the order of the 
particle size. In other words, the smaller the particles, the less distance solute 
must travel. The drawback with small particle size is increased resistance to 
solvent flow. Thus, a smaller particle size requires a higher pressure, but 
provides a shorter optimum run time and lower detection limit (Harris, C.D., 
2010). The temperature used is also of importance. Heating a column usually 
decreases the viscosity of the solvent, thereby reducing the required pressure 
or permitting faster flow. However, increased temperature can also cause 
degradation and decreased lifetime of the column (Harris, C.D., 2010). The 
polarity of the solvent influences the rate of elution of the solute. In reversed 
phase chromatography the column is nonpolar or weakly polar and the 
solvent is more polar. Thus, a less polar solvent has higher eluent strength 
and the solvent molecules will more easily displace the solute molecules on 
the column, resulting in increased elution rate of the solute (Harris, C.D., 
2010). 
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Chemogenetic manipulations 
In paper III, we utilized the ability of the DREADD technique to with a high 
degree of specificity, manipulate non-neuronal signal transduction in a cell-
type-specific manner, and combine this chemogenetic tool with in vivo 
microdialysis. 
Designer receptors exclusively activated by designer drugs (DREADDs) 
DREADDs are a class of chemogenetically-engineered proteins that permit 
temporal as well as spatial control of G-protein signaling in vivo. The 
receptor is solely activated by synthetic ligands such as CNO, when bound 
creates a conformational change in the receptor and activation of the G-
protein. Further effect depends on the type of G-protein (Armbruster et al., 
2007; Roth, 2016). In paper III the technique was used in order to modulate 
the activity of nAc astrocytes and in vivo microdialysis was used to quantify 
extracellular levels of taurine and dopamine in the nAc.  
Three weeks prior to the microdialysis experiment, rats were transfected with 
astrocyte-specific excitatory DREADDs (GFAP-Gq-DREADD) or a control 
plasmid (sham) in the nAc. On the day of microdialysis, animals were 
systemically administrated ethanol and the specific DREADD-ligand CNO, 
and accumbal taurine- and dopamine levels were monitored.  
The DREADDs technique was developed about ten years ago by Bryan Roth 
and colleagues at the University of North Carolina (Armbruster et al., 2007). 
Thus, this is a relatively new technique, which entails a number of concerns. 
One aspect is a potential constitutive activity of the DREADD-receptor. So 
far, there are no reports indicating that. However, just because there are no 
reports showing constitutive activity it does not imply the absence of it. 
Therefore, it is of importance to apply the lowest expression level of the 
DREADDs needed for the current experimental design and to carefully select 
appropriate controls. Another concern is the aspect of receptor regulatory 
processes. Because hM3Dq is subjected to the same regulatory processes 
(phosphorylation, desensitization, internalization, downregulation) as other 
G-protein coupled receptors (Alvarez-Curto et al., 2011) prolonged activation 
with CNO could lead to an attenuated response due to desensitization and/or 
downregulation of hM3Dq. However, no such attenuation of regulatory 
responses has been reported (Alexander et al., 2009; Krashes et al., 2011). 
That this phenomenon would be present in the study of paper III is not very 
likely as no repeated dosing of CNO occur. To date, in most of the studies 
where the technology is used, the DREADDs are expressed in neurons and 
only in a few studies are the receptors expressed in astrocytes. The current 
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opinion is that activation of Gq-DREADDs leads to depolarization of neurons 
and enhances excitability, and activation of inhibitory DREADDs (Gi-
DREADDs) leads to attenuation of neuronal firing (Armbruster et al., 2007; 
Urban & Roth, 2015). However, their functional consequences on astrocytes 
are less known. It has been shown that activation of Gq-DREADDs (which 
are used in paper III) increase [Ca2+]i which is in turn likely to affect 
gliotransmission. A Gq-DREADD expressing astrocyte is then presumed, 
when activated by CNO, to be in an activated state (Agulhon et al., 2013; 
Bull et al., 2014; Scofield et al., 2016; Durkee et al., 2019).  
CNO appears to be pharmacological and behavioral inert in rodents if 
administrated at the recommended dose (0.1-3 mg/kg) (Roth, 2016), which 
was done in paper III. Importantly, CNO can be back metabolized to 
clozapine (Roth, 2016), although to a very low extent. The risk of back-
metabolization of CNO to clozapine should be minimized by administrating 
the lowest possible dose, and adequate controls, where CNO is administrated 
to animals expressing control plasmid (sham), should be used. This is also 
important with regards to reducing possible clozapine-like side effects, such 
as hypotension and sedation. However, the in vivo mechanism of action of 
CNO at DREAADs is debated. Gomez and colleagues (2017) claim that 
CNO is not blood brain barrier (BBB) permeable, and that back-metabolized 
clozapine, derived from systemic administrated CNO, is the ligand for 
DREADDs. Therefore it is suggested that subthreshold doses of clozapine 
should be used instead of high doses of CNO (Gomez et al., 2017) The back-
conversion to clozapine has also been shown to produce clozapine-like 
interoceptive stimulus effects in rodents (Manvich et al., 2018). Additionally, 
clozapine is already approved for clinical use and very low doses of 
clozapine are required for DREADDs activation, reducing undesirable side 
effects. Thus, the use of clozapine, rather than CNO, will most likely increase 
the translational potential of DREADDs as clinical CNS therapy. However, 
the major concern for using DREADDs as CNS therapy would be the 
insertion of an exogenous receptor into the brain. 
Immunohistochemistry 
Immunohistochemistry is a common technique used for detection and 
visualization of proteins (antigens) in a tissue sample. It utilizes the principle 
of antibodies binding to specific antigens and visualization is microscopy-
based. In paper III this method was used to detect and assess astrocyte-
specific DREADD transfection. 
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Even though a fluorescent reporter is connected to the DREADD-construct, 
the signal may need to be amplified. In paper III, the DREADD was HA-
tagged in a vector with IRES-mCitrine and immunohistochemistry with 
fluorescence detection was required for visualization. There are two different 
approaches available for the use of immunohistochemistry: the direct and 
indirect. In comparison with the direct method, the indirect method utilizes 
both a primary antibody and a secondary antibody with a fluorescence 
reporter molecule, which amplifies the signal by increasing the number of 
fluorophore molecules per antigen (Odell & Cook, 2013). In the study with 
astrocyte-specific DREADDs (paper III), a primary anti-HA, anti-GFAP or 
anti-NeuN antibody, and secondary Alexa Flour 488 or Alexa Flour 555 
antibody were used to visualize HA-tagged DREADD and GFAP- or NeuN-
positive cells. 
Sample preparation is critical for successful visualization. This requires 
proper tissue collection, fixation and sectioning. Reduced non-specific 
staining can be achieved by transcardial perfusion of the rats with buffer and 
paraformaldehyde, to postfixation of the brains in paraformaldehyde and by 
applying blocking buffer to the brain slices. The specificity and concentration 
of the antibodies are also significant factors. Furthermore, anti-HA antibody 
also labels areas of damage, e.g. cannula tracks. However, this can be 
distinguished visually and spatially from the HA-antigen. A significant 
problem with immunofluorescence is photobleaching, which results in loss of 
activity of the fluorophore. This can be controlled by increasing the 
concentration of the fluorophores, reducing the timespan or intensity of light 
exposure or by using more robust flourophores that are less prone to 
bleaching, e.g. Alexa Flours as was done in paper III (Ramos-Vara, 2005; Im 
et al., 2019).  
Gene expression 
Gene expression analysis is used to study the occurrence or activity of genes. 
Quantification of mRNA is one way to achieve this, and quantitative 
polymerase chain reaction (qPCR) is the most common approach used. In 
paper II, this method was used to monitor the mRNA levels of several 
different genes (the taurine transporter, several different GABAA receptor 
subunits and glycine receptor subunits, glutamate decarboxylase 1 and 2) 
suggested to be of importance for ethanol-induced taurine and dopamine 
release. The gene expression levels within the nAc between rats systemically 
treated with taurine or vehicle for fifteen days were compared. 
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qPCR is based on conventional polymerase chain reaction (PCR), meaning a 
repetitive series of cycles giving an exponential accumulation of a specific 
DNA (deoxyribonucleic acid) fragment where the number of target DNA 
copies doubles in every PCR cycle. In qPCR, fluorescence is measured in 
every cycle enabling continuous assessment of the amount of PCR product. 
The amount of fluorescence is proportional to the initial amount of template. 
By using complementary DNA (cDNA) transcribed from extracted mRNA as 
template, a relative quantification of mRNA expression in a tissue sample can 
be obtained and comparison between samples can be made (Livak & 
Schmittgen, 2001).  
To decrease a possible impact on the mRNA levels, the animals were 
decapitated without any anesthesia and dissection of the tissue was performed 
in a cold and RNase free manner. Furthermore, the tissue was immediately 
frozen after dissection and stored in -80 °C until RNA extraction and cDNA 
synthesis, which were also performed under RNase free conditions. The 
sensitivity and accuracy of PCR is largely dependent on the specificity of the 
primers used (Thornton & Basu, 2015). In the study of paper II, primers from 
the company Qiagen were used and although the exact sequence is not 
revealed they state high specificity. Furthermore, it is important to note that 
this method does not provide information about the biological function of the 
protein that the target gene is encoding. For instance, a receptor can be 
inactive due to internalization or being in an inactive state even though the 
mRNA expression is high.  
Statistical analysis 
When performing statistical analysis the first step is to consider if to use a 
parametric- or a non-parametric test and is most important with small data 
sets, as the power of non-parametric tests is low. The decision of when to use 
a parametric test and when to use a non-parametric test requires perspective 
and knowledge about the data set and the sample population and is i.a. based 
on whether the data set is assumed to be normally distributed or not. In 
addition, data can be plotted in a histogram and if a bell-shape can be 
detected normal distribution can be assumed. However, this is difficult with 
small sample sizes, as used in this thesis. Another approach is to perform a 
normality test, which is used to determine if data are well modeled by a 
normal distribution and will show a p-value for this. With small sample sizes, 
non-normal distribution is hard to detect with this method due to limited 
power. A third alternative, which is used for statistical analysis in this thesis, 
is to use a quantile-quantile normality plot (Q-Q plot), where the actual 
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residuals are plotted against the predicted residual assuming sampling from a 
Gaussian distribution (Campell et al., 2007).  
Statistical analysis was performed by using GraphPad Prism (GraphPad 
Software, Inc., San Diego, CA, USA). The statistical significance was 
determined by unpaired t-test, one-way analysis of variance (ANOVA) 
followed by Tukey’s multiple comparisons test, two-way ANOVA followed 
by Tukey’s multiple comparisons test, two-way ANOVA with repeated 
measures (treatment group x time) followed by Tukey’s multiple 
comparisons test or Pearson’s correlation coefficient as described in the 
different papers. 
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RESULTS AND DISCUSSION 
Ethanol high-consuming rats show a blunted taurine increase after acute ethanol 
(paper I) 
Chronic ethanol consumption is associated with a decreased activity in the 
mesolimbic dopamine system in both humans and animals (Diana et al., 
1993; Schulteis et al., 1995; Volkow et al., 2007; Connor et al., 2008; 
Feltmann et al., 2016). As taurine appears to be of importance for ethanol to 
increase dopamine in the rat nAc (Ericson et al., 2011), investigating if 
similar adaptations occur with respect to taurine is important. Thus, the aims 
of this study was to assess possible divergences in endogenous levels, as well 
as ethanol-induced increases in extracellular taurine and dopamine levels in 
the nAc of rats voluntary consuming high or low amounts of ethanol. These 
rats will be referred to as ethanol high- and low-consuming animals. 
Blunted increase in taurine following acute ethanol administration in ethanol high-
consuming rats 
By means of in vivo microdialysis we show that neither taurine nor dopamine 
release following an acute systemic injection of ethanol was affected by 
seven weeks of intermittent ethanol consumption when comparing all 
ethanol-consuming rats with ethanol-naïve rats. However, interesting results 
were revealed when the rats were divided by their ethanol consumption into 
high- or low-consuming animals. Although there were no differences in 
endogenous levels of taurine in the nAc, CSF or blood when comparing 
ethanol high- and low-consuming rats (see fig. 3C-E in paper I), we found 
that high-consuming rats exhibited both a reduced and slower increase in 
taurine after acute ethanol treatment as compared to low-consuming rats that 
displayed a normal rapid increase (see fig. 2 in paper I). These findings are in 
line with previous studies performed in ethanol high-preferring and high-
sensitive animals, who displayed reduced but prolonged ethanol-induced 
elevation of taurine, as compared to non-preferring and low-alcohol sensitive 
animals (Quertemont et al., 2000; Quertemont et al., 2002). Thus, there 
appears to be an inverse relationship between the intensity of ethanol-induced 
taurine increase and ethanol intake as well as preference. It has been 
suggested that taurine attenuates the aversive and toxic effects induced by 
ethanol (Watanabe et al., 1985; Quertemont et al., 1998b), which is in 
agreement with the hypothesis of taurine being released to counteract 
ethanol-induced cell swelling, membrane alterations and calcium homeostasis 
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disruption (Quertemont et al., 2000; Olive, 2002). Quertemont and co-
workers suggest that ethanol preferring and high-sensitive rats are not as 
sensitive to the aversive effects of ethanol as their counterparts, non-
preferring and low-sensitive rats, and consequently not as much taurine needs 
to be released (Quertemont et al., 2000; Quertemont et al., 2002). Thus, the 
ethanol high-consuming rats in our study may not be as sensitive to the 
aversive effects of ethanol as the low-consuming rats, and thereby display a 
blunted ethanol-induced taurine release. A reduced sensitivity to the aversive 
effects of ethanol could also be a part of the explanation to why they 
consume more ethanol. Thus, this argues for a pre-existing low dopaminergic 
tone and attenuated reactivity to ethanol-induced taurine elevations. 
However, if the blunted ethanol-induced taurine release displayed in animals 
consuming high amounts of ethanol is a consequence of excessive ethanol 
intake or a pre-existing phenomenon is a question we are not able to answer 
with the results from this study. 
Decreased dopamine tone in ethanol high-consuming animals 
Interestingly, we found that ethanol intake and extracellular levels of 
dopamine, as measured by in vivo microdialysis in the nAc correlate, where 
animals with the lowest dopamine tone consumed the largest amount of 
ethanol (see fig. 1H, I, K, L in paper I). Other studies have also shown that 
repeated high ethanol exposure is associated with low nAc dopamine levels 
in experimental animals (Diana et al., 1993; Kashem et al., 2012; Feltmann et 
al., 2016). The observed correlation between dopamine levels and alcohol 
intake may imply that a low dopamine tone is a risk factor for drinking 
whereas a high dopamine tone is protective. This is supported by the fact that 
high postsynaptic dopaminergic capacity appears to be protective against 
alcohol consumption and AUD (Thanos et al., 2001; Thanos et al., 2005; 
Volkow et al., 2006). However, it could also be the other way around, that an 
excessive alcohol intake reduces dopamine levels, in line with, e.g. Diana and 
colleagues (Diana et al., 1993). A third possibility is a combination of the 
two above, i.e. a low dopamine tone promotes alcohol intake that, if 
excessive, further reduces dopamine levels. 
High-consuming animals display a drinking pattern associated with AUD 
High and low ethanol-consuming animals displayed a different drinking 
pattern, where high-consumers started on a high level of alcohol intake and 
maintained this throughout the study, whereas low-consumers started high 
but rapidly reduced their alcohol intake (see fig. 1B, C in paper I). The 
drinking pattern observed in high-consumers, which intermittently consumed 
large amounts of ethanol, is believed to increase the risk for AUD 
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(Wolffgramm & Heyne, 1995). The different drinking patterns observed in 
high- and low-consumers have been suggested to be related to the anxiety 
level of the animals, as low- and high-consuming animals display high and 
low anxiety-like behavior, respectively. High-consuming rats also show a 
higher risk-taking behavior than low-consuming ones (Momeni & Roman, 
2014). 
We also found that both alcohol intake and endogenous dopamine levels 
varied significantly between subjects. An individual variance is obviously 
present in the human population as well, since some individuals appear more 
resistance and some more sensitive to the development of AUD. Several 
studies emphasize the need for individual screening of animals, which may 
lead to a deeper understanding of the relationship between e.g. the 
dopaminergic status and alcohol intake, as well as of the impact of the 
velocity and magnitude of the ethanol-induced taurine elevation. It is 
possible, or maybe even likely that the outcome in terms of AUD is a 
combination of an underlying spontaneous vulnerability for high/low ethanol 
consumption and ethanol-induced adaptations (Meinhardt et al., 2015). 
In conclusion, the results from this paper suggest that rats consuming high 
amounts of ethanol respond with a blunted taurine elevation in response to 
acute ethanol treatment. Further, ethanol intake correlates to extracellular 
levels of dopamine, where rats with a high ethanol-consumption exhibit a 
lower accumbal dopamine tone than those consuming low levels of ethanol. 
Thus, these data support the previously proposed association between low 
basal dopamine levels and excessive ethanol intake. If and how a blunted 
ethanol-induced taurine response is associated with a decreased dopamine 
tone would be of interest to investigate in future studies. 
The influence of sub-chronic taurine administration on ethanol-induced behavior 
and neurotransmission (paper II) 
As mentioned before, taurine is an important endogenous substance for the 
elevating properties of ethanol (Ericson et al., 2011), and the intake of taurine 
has escalated over the last decade largely due to increased consumption of 
taurine-containing energy drinks (Seifert et al., 2011). Whether long-term 
exposure to large amounts of taurine influences ethanol-induced dopamine 
neurotransmission is not clear. Thus, to explore if repeated exposure to 
taurine affects neurochemical and/or behavioral responses to ethanol, rats 
were daily exposed to large amounts of taurine systemically. The behavior 
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and accumbal transmission were assessed after ten or fifteen days of 
treatment.  
Systemic administration of taurine increases taurine levels in the CNS 
In vitro studies have demonstrated active transport of taurine across the BBB 
(Benrabh et al., 1995; Tamai et al., 1995), and the blood-CSF-barrier 
(BCSFB) into the brain (Chung et al., 1994; Chung et al., 1996). In the 
present study we found that an acute systemic injection of taurine produced 
elevated levels of taurine in accumbal extracellular fluid (see fig. 3 in paper 
II). There is a theoretical possibility that a leakage of taurine from the blood 
into the CNS occurs due to disruption of the BBB caused by the 
microdialysis probe. Therefore, rats without a microdialysis probe were 
systemically administrated taurine. This injection significantly increased 
taurine levels in the blood as well as in the CSF (see fig. 3 in paper II). The 
ability of taurine to pass from the periphery into the brain is further supported 
by the additive effect observed following co-administration of ethanol and 
taurine on nAc taurine levels (see fig. A, B in paper II). 
In our study, taurine’s ability to enter the brain appears not to be altered by 
sub-chronic taurine treatment as no changes in endogenous levels of nAc 
taurine (see fig. 5B) were detected. This is further supported by the fact that 
we did not find any changes in the mRNA expression of the TauT (see fig. 
5A), which indicates that this system is not downregulated by sub-chronic 
taurine exposure. However, others have performed in vitro studies and shown 
that the mRNA expression of TauT is downregulated and the taurine uptake 
into cells reduced following long-term exposure to taurine (Han et al., 1997; 
Bitoun & Tappaz, 2000; Kang et al., 2002; Voss et al., 2004). 
Repeated taurine treatment induces behavioral sensitization but did not influence 
ethanol-induced dopamine elevation 
Repeated taurine treatment did not influence the ability of taurine to enter the 
brain and we found it to induce behavioral sensitization as measured by 
locomotor activity and rearing (see fig. 1 in paper II). Interestingly, daily 
taurine exposure did not have an impact on these behaviors following acute 
administration of taurine and ethanol together (see fig. 1 in paper II). This 
could be a dose-related phenomenon as there are studies demonstrating bi-
phasic effects of taurine on ethanol-induced behavior (Olive, 2002; Fontana 
et al., 2016). It has also been shown that local administration of taurine, 
which results in higher taurine levels in the brain compared with the systemic 
injection administrated in paper II, decreases locomotion (Garcia de Yebenes 
Prous et al., 1978). We show that co-administration of ethanol and taurine 
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produce an additive increase in accumbal taurine (see fig. 2A, B in paper II). 
Thus a theoretical possibility is that the co-administration results in such high 
taurine levels that signaling systems that will counteract locomotion become 
activated. For example taurine is known to exert agonistic effects at the 
GABA receptor (Huidobro-Toro et al., 1987; Olive, 2002), a receptor known 
to be involved in the sedating effects within the CNS (Brohan & Goudra, 
2017).  
In this paper we also demonstrated that sub-chronic taurine treatment did not 
have an impact on ethanol-induced dopamine elevation in the nAc (see fig. 
6E, F). This could be explained by a tight regulation of brain taurine 
concentrations during fluctuations in taurine blood concentrations 
(Lefauconnier et al., 1978), or, as previously suggested, that only a small 
amount of taurine is needed as a co-factor for ethanol-induced dopamine 
elevation (Ericson et al., 2011; Soderpalm et al., 2017), making the extra 
amount of taurine redundant. This latter suggestion is further supported by 
the finding that no additive effect on ethanol-induced dopamine levels was 
produced when co-administrated with taurine (see fig. 2C, D in paper II). It 
could also be that the dose of taurine and/or treatment time was not sufficient 
to induce adaptations. However, in a recent (unpublished) study performed in 
our laboratory we found that rats administrated taurine-enriched (2% taurine) 
drinking water for five weeks were exposed to a higher dose of taurine (1.66 
g/kg/day) per day compared to the systemic injections in this paper (II). 
Nevertheless, no changes in taurine or dopamine levels following acute 
ethanol treatment were found, as compared to water-drinking control 
subjects. Administrating even higher concentrations of taurine may include 
the risk of using physiologically irrelevant concentrations.  
The consumption of taurine-containing energy drinks together with ethanol 
has been shown to be associated with severe consequences, such as increased 
alcohol intake and harmful behavior (Marczinski, 2011; Seifert et al., 2011; 
Caviness et al., 2017). Although we did not find any impact of sub-chronic 
taurine administration on ethanol-induced dopamine increase, exposure to 
large amounts of taurine during a longer period of time could still have an 
impact on positive reinforcement since taurine induced behavioral 
sensitization. A possible mechanism may involve the postsynaptic side of the 
dopaminergic system, as behavioral sensitization has been linked to enhanced 
dopamine release and increased postsynaptic dopamine receptor sensitivity 
(Fung & Lau, 1988; Akimoto et al., 1989; Kazahaya et al., 1989; Molander 
& Soderpalm, 2003). 
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We conclude that systemically administrated taurine has the ability to enter 
the CNS in physiologically relevant concentrations, and that this is not 
influenced by sub-chronic taurine treatment. Although, sub-chronic taurine 
exposure does induce behavioral sensitization to the drug, it does not 
influence the dopamine elevating properties of ethanol. However, further 
studies are needed to evaluate if frequency, length or dose of taurine exposure 
will have an impact of ethanol-induced taurine and dopamine elevation in the 
nAc.  
The role of astrocytes in regulating taurine and dopamine interactions during 
ethanol exposure (paper III) 
One of taurine’s fundamental actions is to act as an osmoregulator (Huxtable, 
1992), where taurine is released from the cell into the extracellular space to 
counteract cell swelling induced by a decreased osmolarity in the 
extracellular environment (Solis et al., 1988; Pasantes-Morales et al., 1993; 
Moran et al., 1994a; Vitarella et al., 1994; Deleuze et al., 1998). As ethanol 
changes the extracellular milieu and induces cell-swelling (Kimelberg et al., 
1993; Allansson et al., 2001; Adermark et al., 2011b), we hypothesized that 
taurine is released for osmoregulatory purposes following acute ethanol 
exposure (Ericson et al., 2011). However, the origin of ethanol-induced 
taurine release is not known. Thus, in order to determine if the rise in 
accumbal taurine after ethanol exposure mainly derives from neurons or 
astrocytes and if VRACs are involved, both pharmacological and 
chemogenetic manipulations of the rat nAc were performed.  
Ethanol-induced taurine increase in not dependent on action potentials 
As a result of perfusion with TTX in the nAc, we conclude that the rise of 
accumbal taurine levels following ethanol are independent of action potential 
mediated neurotransmission (see fig. 2A, C in paper III). This suggests that 
taurine release in the nAc after ethanol exposure derives from astrocytes, 
which also has been suggested based on findings in cell cultures (Kimelberg 
et al., 1993; Aschner et al., 1998). Arguing against this suggestion is the fact 
that metabolic inhibition of astrocytes by fluorocitrate failed to block the 
ethanol-induced increase (see fig. 5B, D). However, osmoregulation is an 
essential feature for maintaining cell volume homeostasis (Huxtable, 1992). 
Thus, if taurine is released for osmoregulatory purposes to counteract cell 
swelling induced by ethanol, fluorocitrate administration may not be 
sufficient to antagonize this basal mechanism, which is essential for cell 
survival. To further assess the role of nAc astrocytes in ethanol-induced 
taurine elevation we used astrocyte specific excitatory Gq-DREADDs. 
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Interestingly, chemogenetic activation of accumbal astrocytes not only 
potentiated the ethanol-induced taurine increase (see fig. 4B, C), it also 
potentiated the dopamine release during ethanol exposure (see fig. 4E, F). 
Additionally, when we used the opposite approach and decreased astrocyte 
activity by metabolic inhibition we found a reduction in ethanol-induced 
dopamine levels. Thus, the degree of activation or inhibition of the astrocyte 
appears to have an impact on dopamine levels following ethanol exposure, 
which further supports a significant role of this cell-type in ethanol-induced 
dopamine transmission (Adermark & Lovinger, 2006; Adermark et al., 
2011b; Bull et al., 2014).  
Ethanol-induced taurine release involves VRACs 
VRAC is a swelling-activated channel that regulates cell volume. Upon 
activation it mediates the efflux of Cl- and organic molecules such as taurine 
(Hoffmann et al., 2009; Jentsch, 2016; Strange et al., 2019). Increased efflux 
of taurine via the VRAC occurs within minutes following hypotonic exposure 
(Lambert et al., 2015). As ethanol changes the extracellular environment and 
induces swelling of astrocytes (Kimelberg et al., 1993; Allansson et al., 
2001; Adermark et al., 2011b), in paper III we aimed to investigate the 
possibility that taurine may be released via VRACs to counteract ethanol-
induced cell swelling. We found that VRAC antagonism reduced nAc taurine 
during ethanol exposure (see fig. 6B, D), further supporting the hypothesis 
that taurine is released due to osmoregulation. Although these channels are 
found both on astrocytes and neurons (Akita & Okada, 2014), the following 
circumstances argue for VRACs on astrocytes to be involved in ethanol-
induced taurine release: astrocytes are the cell type predominantly involved 
in osmoregulation (Kimelberg et al., 1992), where taurine acts as one of the 
primary osmolytes, and as mentioned above, ethanol induces cell swelling of 
astrocytes (Kimelberg et al., 1993; Allansson et al., 2001; Adermark et al., 
2011b). However, there is a possibility that other mechanisms than 
osmoregulation could be involved since increased taurine levels in the 
amygdala were detected after saline administration together with a 
conditioned ethanol-associated olfactory stimulus (Quertemont et al., 1998b). 
However, this remains to be determined in future studies.  
Based on the present study we suggest that ethanol-induced accumbal taurine 
release derives mainly from astrocytes and involves VRACs. We also suggest 
that increased or decreased activation of astrocytes and VRACs contribute to 
the regulation of dopamine levels following ethanol administration.  
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Energy drink constituents (caffeine and taurine) selectively potentiate ethanol-
induced locomotion in mice (paper IV) 
Not only is the consumption of the combination of energy drinks and alcohol 
associated with increased risk for binge drinking and development of AUD 
(Price et al., 2010; Arria et al., 2011), people consuming this mixture also 
display an impaired judgement and consequently expose themselves and 
others for risks (Ferreira et al., 2006; O'Brien et al., 2008; Marczinski et al., 
2012). If this is a result of a pharmacological interaction is not yet clear. 
Therefore it is of importance to study the interplay between two of the 
common energy drink ingredients, caffeine and taurine, on ethanol-induced 
behavior. Thus in this study three different doses of ethanol, four different 
doses of caffeine and four different doses of taurine were administered to 
mice and locomotor activity was assessed. Locomotor activity was used, as 
this is a straightforward model suitable for screening several doses of a drug. 
It is also known that moderate doses of ethanol increase locomotor activity in 
mice, an effect linked to the ability of ethanol to activate the mesolimbic 
dopamine system (Carlsson et al., 1974; Liljequist et al., 1981; Wise & 
Bozarth, 1987; Engel et al., 1988).  
Caffeine has an additive effect on ethanol-induced locomotion 
In this study three different doses of ethanol were tested in the locomotor 
activity boxes. This was done in order to study the influence of caffeine and 
taurine on the locomotor stimulatory effect of ethanol, as well as on non-
stimulatory ethanol doses. We found the middle dose (2.5 g/kg) of ethanol to 
have a stimulatory effect on locomotion, which is in line with previous 
studies (Liljequist, 1991; Blomqvist et al., 1994). We also found caffeine to 
increase locomotion (see fig. 1C, D in paper IV), which could be linked to its 
ergogenic and hypothermic effects, as this has been discussed to be 
associated to changes in dopamine transmission (Quarta et al., 2004; De Luca 
et al., 2007; Zheng et al., 2014). Interestingly, we showed that caffeine in 
specific doses potentiated the ethanol-induced locomotor activity (see fig. 
2B-D in paper IV). The mechanisms underlying this interaction are not clear 
but it has been suggested that caffeine enhances locomotion by increasing 
dopaminergic neurotransmission in the nAc by antagonism of the adenosine 
receptors (El Yacoubi et al., 2000; Karcz-Kubicha et al., 2003; Quarta et al., 
2004; Kuzmin et al., 2006), and that ethanol, besides increasing dopamine 
signaling in the nAc may enhance locomotion through interactions in the 
adenosinergic system (Nagy et al., 1990; Krauss et al., 1993; Arolfo et al., 
2004; Lopez-Cruz et al., 2013; Nam et al., 2013). Thus, this interaction may 
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be related to the drugs’ combined effects on the mesolimbic dopamine 
system by modulating adenosine-signaling.  
Taurine when administrated together with caffeine has a pronounced impact on 
ethanol-induced locomotion in naïve and caffeine experienced mice  
Even though no influence of taurine could be seen when administered alone 
(see fig. 1E, F in paper IV), or in combination with ethanol (see fig. 3 in 
paper IV), we demonstrated that the combination of caffeine and taurine, at a 
specific dose combination, potentiated ethanol-induced locomotor activity 
compared to either drug alone (see fig. 4C in paper IV). As a large proportion 
of the human population has a continuous intake of caffeine, due to coffee 
consumption on a regular basis, it is of interest to explore the influence of 
caffeine and taurine on ethanol-induced locomotion in caffeine experienced 
animals. We found caffeine to induce behavioral sensitization to the drug (see 
fig. 5B in paper IV). Interestingly, the additive effect of the combination of 
caffeine and taurine on ethanol-induced locomotion was still present in these 
caffeine-sensitized animals (see fig. 5D in paper IV). Thus, even though not 
having an influence alone, taurine together with caffeine has a pronounced 
impact on ethanol-induced behavior. An interaction of caffeine and taurine on 
ethanol-induced behavior is further supported by a study where oral “energy 
drink” (containing caffeine and taurine) administration decreased the 
depressant effects of ethanol on locomotor activity and by that a modest 
ethanol-induced behavioral sensitization was increased by oral administration 
of this “energy drink” (Ferreira et al., 2004; Ferreira et al., 2013). Future 
studies are needed to elucidate the mechanisms underlying this observed 
potentiation, where joint targets may consist of GABAA, glycine and NMDA 
receptors as well as calcium signaling, as all these are affected by both 
caffeine and taurine (Nehlig et al., 1992; Schaffer et al., 2000; Olive, 2002; 
Quarta et al., 2004; Chan et al., 2014). 
Taken together we suggest that the combination of caffeine and taurine, at a 
specific combination of doses, increases ethanol-induced locomotion, a 
phenomenon previously linked to the reinforcing properties of the drug. 
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GENERAL DISCUSSION 
Only a few pharmacotherapies are available for AUD with limited efficacy 
and with varying effects in patients, likely due to the complexity and 
heterogeneity of the disease (Heilig & Egli, 2006). Considering the severe 
consequences associated with excessive alcohol use and the enormous costs 
for the society there is a significant need for improved therapies. To enable 
development of this, a deeper understanding and knowledge about the 
processes involved in excessive alcohol intake and the development of 
addiction are needed. Changes in the mesolimbic dopamine system are 
thought to be a predominant underlying factor in excessive alcohol intake and 
AUD (Volkow et al., 1996; Volkow et al., 2007), and resent research has 
suggested taurine to play a central role in the dopamine elevating properties 
of ethanol. Thus the purpose of this thesis was to investigate correlations 
between taurine and dopamine during ethanol exposure, with special 
emphasis on neurochemical effects in the nAc. 
In this thesis we show that ethanol increases extracellular levels of both 
taurine and dopamine in the nAc as measured by in vivo microdialysis. This 
occurred both in naïve (paper I, II, III) as well as in ethanol (paper I) or 
taurine (paper II) experienced animals, and when ethanol was systemically 
administrated by an i.p. injection (paper I, II, III) or by local perfusion via the 
microdialysis probe into the nAc (paper III ) (table 2). In our studies ethanol, 
when systemically or locally administrated, increases accumbal taurine levels 
by approximately 40-60% (calculated as % of pre-drug baseline) in naïve 
animals, with some individual variance as well as variance between batches 
of animals. This is in line with the observed increase of taurine reported in 
some studies (Dahchour et al., 1996; Smith et al., 2004), but lower than what 
was reported in other studies (Dahchour et al., 1994; Quertemont et al., 
2003). In our hands, systemic administration of ethanol increases dopamine 
levels by approximately 40-60%, whereas local perfusion of ethanol in the 
nAc increases dopamine levels by approximately 20-40%. Both the ethanol-
induced taurine and dopamine elevation peaks at about the same time point 
after administration; at twenty minutes after an i.p. injection of ethanol, 
whereas the peaks tend to appear slightly later (about 20-40 minutes after the 
perfusion starts) during local perfusion of the drug. Thus the presented data 
in this thesis indicate that ethanol-induced taurine and dopamine elevations in 
the nAc are robust phenomena that occur simultaneously, despite different 
routes of administration and previous ethanol or taurine experience (table 2).  
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Table 2. Summary of the effects of different treatments on ethanol-induced 
taurine and dopamine levels as compared to baseline, and how the 
treatments relate to the effects produced by ethanol in naïve (untreated) rats. 
All measurements were performed on samples obtained from the nucleus 
accumbens by means of in vivo microdialysis. More detailed results can be 
found in papers I, II and III.  TTX=tetrodotoxin, Gq-DREADDs=excitatory 
designer receptor exclusively activated by designer drugs, VRAC=volume 
regulation anion channel, n.s.=non-significant. 
 TAURINE DOPAMINE 
Treatment 
Treatment
+ethanol 
vs. 
baseline 
Treatment
+ethanol 
vs. 
Untreated
+ethanol 
Treatment
+ethanol 
vs. 
baseline 
Treatment
+ethanol 
vs. 
Untreated
+ethanol 
Acute taurine 
treatment  é é é n.s. 
Repeated taurine 
treatment é n.s. é n.s. 
Repeated ethanol 
exposure é n.s. é n.s. 
Action potential 
inhibition (TTX) é é ê ê 
Astrocyte activation  
(Gq-DREADDs) é é é é 
Astrocyte inhibition 
(Fluorocitrate) é é é ê 
VRAC inhibition 
(DCPIB) é ê n.s. ê 
 
We and others have suggested that taurine and dopamine are closely related 
with regards to ethanol’s actions within the mesolimbic dopamine system 
(Olive, 2002; Ericson et al., 2011; Soderpalm et al., 2017). This is further 
supported by data presented in this thesis, since following pharmacological or 
chemogenetic manipulations, the direction of changes (increase or decrease) 
in ethanol-induced dopamine increase appears to follow the direction of 
changes in ethanol-induced taurine increase. As in paper III, the ethanol-
induced dopamine and taurine levels were either both increased or decreased 
following treatment with CNO and ethanol in Gq-DREADDs transfected 
animals or with DCPIB and ethanol in naïve animals, respectively. Also, both 
the taurine and dopamine increase after acute ethanol remains unaffected by 
intermittent ethanol consumption (paper I) or sub-chronic taurine treatment 
(paper II) as compared to naïve animals. However in paper III, treatment with 
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fluorocitrate increased the taurine levels but decreased dopamine levels after 
ethanol treatment, which would argue against the importance of endogenous 
taurine as an essential component for ethanol-induced dopamine levels in the 
nAc (table 2). 
That taurine is involved in the rewarding sensation of ethanol is however 
further supported by a study from Li et al, showing that accumbal taurine 
levels increased during the 15 first minutes during operant ethanol self-
administration, and that the degree of taurine increase was positively 
correlated with the amount of ethanol consumed. Interestingly, this study also 
suggested that the two glycine receptor ligands, taurine and glycine, play 
different roles in the rewarding actions of ethanol. The greatest increase of 
glycine levels in the nAc was observed with the longest time-out period 
during operant ethanol self-administration, suggesting that glycine is 
involved in the anticipation of ethanol reward and taurine appears to be more 
involved in the reward itself (Li et al., 2008).  
The mechanism underlying the increase of taurine release following ethanol 
administration is not fully understood. In paper III, we hypothesized that the 
ethanol-induced taurine increase in the accumbal extracellular space is 
primarily due to osmoregulation and that taurine may be released via VRACs 
located on astrocytes. We found that antagonism of VRACs reduced ethanol-
induced taurine levels and that taurine release following ethanol is 
independent of action potential firing, further supporting this hypothesis. 
Others have suggested that ethanol-induced taurine release may be due to 
neuronal depolarization (Smith et al., 2004), which is further supported by 
the finding that taurine can be found in synaptic vesicles (Huxtable, 1992), 
and that depolarization of neurons result in taurine release (Kaczmarek & 
Davison, 1972; Collins & Topiwala, 1974; Shain & Martin, 1990). 
Furthermore, there appears to be regional selectivity with regards to ethanol’s 
taurine enhancing effects as the ethanol-induced taurine increase was lower 
in the dorsal striatum compared to the nAc (Smith et al., 2004). This is 
further supported by the finding that ethanol diluted in a hypertonic saline 
solution does not prevent ethanol from increasing taurine in the dorsal 
striatum (Ulenius et al., 2017) in contrast to what was shown in the nAc 
(Ericson et al., 2011). This would also argue against osmoregulation as the 
sole mechanism of action underlying ethanol’s ability to increase taurine. 
Nevertheless, there is also a possibility that the ethanol-induced taurine 
elevation in the nAc derives from an increased biosynthesis. This is however 
not likely since the taurine turnover in the brain is slow, about 5 days 
(Collins, 1974; Spaeth & Schneider, 1974; Wright et al., 1986). Another 
possibility would be that ethanol negatively interferes with the taurine 
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transporter, thereby preventing taurine uptake into e.g. astrocytes. However, 
this appears unlikely as ethanol did not interfere with the transport of taurine 
into the brain after systemic administration of taurine (paper II).  
Although, based on the studies presented in this thesis (paper II and paper 
III), we suggest that ethanol-induced taurine release in the nAc mainly 
derives from central sources, more specifically astrocytes, we cannot totally 
discard a contribution of taurine from the periphery. Taurine has the ability to 
cross both the BBB (Benrabh et al., 1995; Tamai et al., 1995) and BCSFB 
(Chung et al., 1994; Chung et al., 1996) and in vitro studies have shown that 
short-term administration of ethanol impairs the BCSFB (Nixon et al., 2008) 
and affect cytoskeletal and tight junctions proteins, which leads to an 
impairment of the BBB (Haorah et al., 2005). On the other hand, Stewart and 
colleagues show that acute ethanol administration does not affect the 
permeability of horseradish peroxidase from the BBB (Stewart et al., 1988). 
Thus, circulating taurine from the periphery could constitute a part of the 
observed taurine increase in the nAc following ethanol treatment, but further 
studies are needed to determine this. Despite origin and mechanism of action, 
it is likely that taurine has a neuronal impact. Taurine increases chloride 
conductance to hyperpolarize membranes, probably via activation of GlyR 
and GABAR (Okamoto et al., 1983b; Ye et al., 1997). As GlyRs are 
expressed in the nAc (Martin & Siggins, 2002; Molander & Soderpalm, 
2005b; a; Forstera et al., 2017), it is likely that taurine, via GlyR in the nAc, 
influence ethanol-induced dopamine release via the proposed nAc-VTA-nAc 
circuitry (Soderpalm et al., 2009). And given the modulatory role of 
astrocytes in neuronal function (Walz, 2000; Akita & Okada, 2014; 
Adermark & Bowers, 2016) it is reasonable to think, as proposed in paper III, 
that these cells indirectly (via taurine) influence ethanol-induced dopamine 
levels. 
Increased extracellular levels of taurine following ethanol exposure have 
been found in other regions of the brain than in the nAc, such as amygdala 
(Quertemont et al., 1998a; Quertemont et al., 1999), hippocampus (Dahchour 
& De Witte, 1999) and dorsal striatum (Smith et al., 2004; Ulenius et al., 
2017). However, the mechanism by which this occurs appears to differ as 
administration of ethanol in a hypertonic saline solution did not prevent 
ethanol from increasing taurine or dopamine levels in the dorsal striatum 
(Ulenius et al., 2017), whereas it did in the nAc (Ericson et al., 2011). In the 
amygdala, taurine has been proposed to derive mainly from neurons 
(Quertemont et al., 1999), since taurine has been detected in most of the 
neurons but only in a small portion of the astrocytes of the amygdala 
(Ottersen et al., 1986), whilst we in paper III suggest that ethanol-induced 
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taurine release in the nAc mainly derives from astrcoytes. Thus there may be 
regional differences regarding both the origin of ethanol-induced taurine 
release as well as the underlying mechanisms of action. 
The regulation of total body content of taurine seems to be rather rigorous as 
the rate of biosynthesized taurine is constant, and when dietary taurine is 
increased the half-life of elimination of biosynthetically derived taurine is 
decreased (Huxtable & Lippincott, 1982). This was demonstrated in cats fed 
a taurine-rich diet, which within days upregulated their secretion of taurine 
via the urine (Glass et al., 1992). In line with these findings we did not find 
sub-chronic taurine treatment to affect the endogenous levels of extracellular 
taurine in the nAc (paper II). However, only a prolonged increase of taurine 
intake or depletion appears to cause changes in plasma taurine concentration, 
and a correlation between whole blood taurine and plasma taurine levels have 
been suggested to be found only following extremes of taurine depletion or 
taurine supplementation (Trautwein & Hayes, 1995). In line with this, it has 
been shown that vegans display lower plasma taurine concentration as well as 
decreased excretion of taurine via the urine (Rana & Sanders, 1986; Laidlaw 
et al., 1988). In paper II, we found that sub-chronic taurine treatment did not 
influence extracellular levels of taurine in the nAc. In this study we did not 
measure taurine plasma concentrations after sub-chronic taurine treatment, 
raising the possibility of changed plasma concentrations. However, even if 
the taurine plasma concentration was changed it is likely that this would not 
effect accumbal extracellular taurine levels, since it has been shown that 
brain taurine concentrations are kept constant during changes in plasma 
taurine concentration (Lefauconnier et al., 1978). Although patients with 
AUD display decreased levels of taurine in the blood, as compared to 
nonalcoholic individuals (Majumdar et al., 1983), we found that intermittent 
voluntary ethanol consumption did not influence the endogenous levels of 
taurine in serum, or in the CSF or in the extracellular fluid of the nAc (paper 
I). This could mean that the time-period for ethanol consumption in paper I is 
too short in order to induce changes in endogenous taurine levels. Another 
alternative is that the decreased taurine levels found in AUD-patients are due 
to an overall malnutrition.  
Finally, the question arises whether acute or repeated intake of large amounts 
of taurine is harmful with regards to excessive alcohol consumption and the 
development of AUD. Based on the studies presented in this thesis taurine 
could, probably together with caffeine, play a role in the reported increased 
alcohol consumption in humans drinking alcohol mixed with energy drinks as 
we found that the combination of caffeine and taurine had an additive 
influence on ethanol-induced locomotion (paper IV). We also found that sub-
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chronic taurine treatment did not influence the dopamine elevating properties 
of ethanol, but did induce behavioral sensitization to taurine (paper II). The 
former speaking against and the latter arguing for the ability of taurine to 
influence positive reinforcement. Putting these findings together with 
previous studies (see “Interactions between taurine and ethanol in the CNS” 
in the introduction of this thesis) it appears that the effects of taurine on 
ethanol-induced dopamine and dopamine-related behavioral effects are 
largely dependent on the dose of the drugs as well as time of treatment 
period. Thus we cannot conclude that acute or repeated intake of large 
amounts of taurine is innoxious with regards to excessive alcohol 
consumption, and further studies are needed to determine this. With respect 
to taurine’s actions in the periphery (Huxtable, 1992), excessive intake of 
large amounts of taurine may produce adverse effects on peripheral organs, 
such as the heart. For example, the intake of energy drinks is associated with 
adverse cardiovascular effects, particularly on blood pressure and heart rate. 
These effects are thought to be mediated by caffeine and a possible 
combination of caffeine and taurine (Grasser et al., 2016). The detailed 
peripheral actions of taurine are however a discussion beyond this thesis.  
The anti-craving substance and homotaurine analogue acamprosate has been 
shown to reduce ethanol-intake in laboratory animals (Boismare et al., 1984; 
Czachowski et al., 2001; Olive et al., 2002; Cowen et al., 2005; Gupta et al., 
2008; Chau et al., 2010a; Lido et al., 2012), an effect suggested to be related 
to the drug’s dopamine elevating properties (Olive et al., 2002; Cowen et al., 
2005; Chau et al., 2018). Similar to both taurine (Ericson et al., 2006; 
Ericson et al., 2011) and ethanol (Blomqvist et al., 1993; Blomqvist et al., 
1997; Ericson et al., 2003; Molander & Soderpalm, 2005a), the dopamine 
action of acamprosate has been shown to involve GlyR in the nAc and 
nAChR in the VTA (Chau et al., 2010b). Interestingly, taurine modestly 
reduces ethanol consumption in rats (Olive, 2002). Thus, theoretically there is 
a possibility that taurine could be used as treatment for patients suffering 
from AUD.   
In conclusion, based on the results presented in this thesis we suggest that 
increased accumbal taurine levels following ethanol exposure is a robust 
phenomenon, mainly derives from astrocytes and involves VRACs. 
Furthermore, we suggest that sub-chronic, systemic administration of taurine 
may have long-lasting effects on the brain, in the present thesis displayed as 
behavioral sensitization, but that ethanol-induced dopamine release is not 
affected. We also conclude that a low dopamine tone in nAc is associated 
with excessive ethanol intake and that the active state of the astrocytes 
appears to influences dopamine levels following acute ethanol exposure. 
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Finally, we suggest that taurine could, probably together with caffeine, have a 
role in the reported increased alcohol consumption in humans drinking 
alcohol mixed with energy drinks.  
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FUTURE PERSPECTIVES 
Based on studies presented in this thesis we can conclude that ethanol-
induced taurine release in the nAc is a robust phenomenon. Studying the 
underlying mechanisms behind this phenomenon is important as it may 
contribute to furthering the knowledge about how ethanol increases accumbal 
dopamine levels. Although we suggest that taurine release following ethanol 
exposure mainly derives from astrocytes, involves VRACs and occurs due to 
osmoregulation, it needs to be further evaluated. Except for the VRAC 
inhibitor DCPIB, used in this thesis, there are a number of anion channel 
inhibitors, such as DIDS, SITS, NPPB and carbenoxolone, that can be used 
for inhibiting VRACs (Friard et al., 2017). Additionally, to further evaluate 
the role of VRACs whole cell patch clamp electrophysiology recordings can 
be used for measuring VRAC-mediated chloride currents (Strange et al., 
2019) following ethanol exposure. To outline the involvement of astrocytes 
in ethanol-induced taurine release it would be beneficial to chemogenetically 
inhibit astrocytes by astrocyte-specific inhibitory DREADDs and, as was 
done in paper III, monitor taurine and dopamine levels by in vivo 
microdialysis.  
There are studies showing increased taurine levels after i.p. injections of 
ethanol in doses that animals will self-administer (Smith et al., 2004), and 
during operant ethanol self-administration (Li et al., 2008), but to my 
knowledge there are no studies investigating accumbal taurine and dopamine 
levels during oral voluntary ethanol consumption. This is an important aspect 
as alcohol consumption in humans occurs both voluntary and orally and 
should be investigated in future studies.  
As high ethanol-consuming animals display a lower tone of dopamine in the 
nAc as well as a blunted ethanol-induced taurine release (paper I), it would 
be beneficial to determine if this hypo-dopaminergic state is a preexisting 
phenomenon or if it develops over time as a consequence of excessive 
alcohol consumption. Theoretically this may be investigated by using guide 
cannulas for insertion of a microdialysis probe, enabling measurement of 
dopamine before and after excessive ethanol intake. Regardless of whether it 
is a preexisting phenomenon or not, a dopamine stabilizer, which has the 
ability to inhibit or stimulate dopamine-related behaviors depending on the 
prevailing dopaminergic tone (Sonesson et al., 1994; Rung et al., 2008), 
would constitute a beneficial pharmacotherapy (Feltmann et al., 2016). Thus, 
regardless of a low or high dopaminergic tone and how it changes over time 
during prolonged ethanol intake, a dopamine stabilizer would normalize the 
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dopaminergic tone and consequently reduce ethanol intake. A dopamine 
stabilizer has been demonstrated to counteract downregulated accumbal 
dopamine output in long-term ethanol consuming rats (Feltmann et al., 
2016), and should be further evaluated for being used for attenuating alcohol 
intake in AUD-patients. 
As increased locomotor activity induced by ethanol is linked to activation of 
the mesolimbic dopamine system (Carlsson et al., 1974; Liljequist et al., 
1981; Wise & Bozarth, 1987; Engel et al., 1988), it is commonly used for 
studying drug-induced behavioral effects related to the brain reward system. 
Since we found the combination of caffeine and taurine to have an additive 
impact on ethanol-induced locomotion, it may imply that this combination 
gives rise to a more intense activation of the reward system and consequently 
a lager positive reinforcing effects than ethanol alone. This could potentially 
be one of the reasons to why humans drinking alcohol mixed with energy 
drinks display an increased alcohol intake. Thus, the next step would be to 
determine if the drug-combination will have an additive impact on nAc 
dopamine levels following ethanol exposure. To this end, naïve rats as well 
as ethanol-experienced rats will be administered taurine, caffeine and ethanol, 
subsequently taurine and dopamine levels will be monitored by means of in 
vivo microdialysis. As the rate of dopamine elevation has been correlated 
with the subjective feeling of pleasure (Volkow et al., 1999; 2003; Koob & 
Volkow, 2016), sampling every ten minutes instead of the regular twenty-
minute sampling protocol would reveal not only the amount of drug-induced 
taurine and dopamine levels but also the rate of increase. Commonly, as well 
as in this thesis, in vivo microdialysis is coupled with HPLC to analyze the 
extracellular levels of taurine and other amino acids. However, one should 
consider using capillary electrophoresis coupled with laser-induced 
fluorescence detection (CE-LIF) instead of HPLC, which will provide a 
higher sensitivity and temporal resolution enabling detection of subtle 
changes of dopamine and amino acids such as taurine (Lada & Kennedy, 
1996; Bowser & Kennedy, 2001; Bert et al., 2002; Smith et al., 2004). 
Finally, investigating whether caffeine and/or taurine influence the behavioral 
effects and subjective experience of ethanol in human laboratory studies is 
important considering the consumption by the young population.  
Except taurine’s interaction with ethanol and its potential involvement in 
AUD, a number of other interesting actions of the amino acid within the CNS 
have been demonstrated, such as anxiolytic and antidepressant effects, where 
it has been suggested to interact with dopamine and GlyR (Wu et al., 2017; 
Jung & Kim, 2019). The potential anxiolytic effect of taurine has been 
demonstrated in animal models (Chen et al., 2004; Kong et al., 2006; Jung & 
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Kim, 2019), however the mechanism of action is not fully understood. Jung 
and co-workers (2019) have shown that taurine does not exert its anxiolytic 
effect through the GABAAR or by influencing the GABA synthesis. They 
suggest that taurine reduces anxiety via strychnine-sensitive GlyR (Jung & 
Kim, 2019), which is further supported by another laboratory (Komatsu et 
al., 2015). Interestingly, Jung et al also propose that taurine-induced 
anxiolytic behavior may be mediated by dopamine regulation as taurine has 
been shown to increase dopamine (Ericson et al., 2003). One of the 
hypothesis of the pathogenesis of depression is the monoaminergic 
hypothesis, which state that depression is probably due to a deficiency in 
monoamine neurotransmitters including 5-HT, dopamine and noradrenaline 
(Lopez-Munoz & Alamo, 2009). Subjects in a rat model of depression 
display lower levels of these neurotransmitters, changes that were prevented 
by administration of taurine (Wu et al., 2017). It was suggest that this occurs 
by a direct regulation of the neurotransmitters by taurine, or by an indirect 
action of taurine via regulation of the hypothalamic-pituitary-adrenal axis 
(Wu et al., 2017).  Thus, the interaction of taurine and dopamine within the 
CNS may not be solely interesting with regards to ethanol. Their influence on 
and interaction with other psychiatric disorders would be interesting to 
include in future studies.  
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